CN114671878A

CN114671878A - Substituted nitrogen-containing bicyclic compounds and uses thereof

Info

Publication number: CN114671878A
Application number: CN202111589877.5A
Authority: CN
Inventors: 池波; 张铮; 韩伟; 马发城; 刘楚怡; 王慧; 詹志柱; 贺艳; 左应林; 王晓军
Original assignee: Sunshine Lake Pharma Co Ltd
Current assignee: Guangdong HEC Pharmaceutical
Priority date: 2020-12-25
Filing date: 2021-12-23
Publication date: 2022-06-28
Anticipated expiration: 2041-12-23
Also published as: CN114671878B; WO2022135534A1

Abstract

The invention discloses a substituted nitrogen-containing bicyclic compound and application thereof. In particular, the invention relates to a novel class of substituted nitrogen-containing bicyclic compounds and pharmaceutical compositions comprising the same, which can be used as chymase inhibitors. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparing medicaments for treating cardiovascular diseases related to heart failure or myocardial infarction and the like.

Description

Substituted nitrogen-containing bicyclic compounds and uses thereof

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to substituted nitrogen-containing bicyclic compounds and application thereof, and further relates to a pharmaceutical composition containing the compounds, and a using method and application thereof. In particular, the substituted nitrogen-containing bicyclic compound and/or the pharmaceutical composition thereof can be used as a chymotrypsin-like inhibitor for preventing, treating or relieving heart failure, myocardial infarction and other related cardiovascular diseases.

Background

Cardiovascular diseases (CVD) are one of the leading causes of death worldwide. CVD refers to ischemic or hemorrhagic diseases of heart, brain and general tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc., such as hypertension, coronary artery disease, myocardial disease, vascular disease, congenital heart disease, arrhythmia, pericardial disease, heart attack, stroke, etc. Hypertension, high cholesterol, smoking, obesity and diabetes are major risk factors that contribute to the development of cardiovascular disease. Lifestyle, age, and family history also increase the risk of heart disease. Although age, gender, genetic and family history are unalterable risks of susceptibility to cardiovascular disease, the burden of cardiovascular disease can be reduced by implementing low fat and low sodium diets, maintaining physical activity and avoiding weight gain. Recent preclinical and several clinical studies point to a relatively unrecognized fact that chymase inhibitors may have significant therapeutic advantages over other therapeutic approaches in arresting the progression of cardiac and vascular disease.

Chymotrypsin-like (Chymase) is a chymotrypsin-like serine protease whose macromolecular complex with heparin proteoglycans is stored in the secretory vesicles of mast cells. After mast cells are activated, chymase is released to the extracellular matrix in response to inflammatory signals, tissue damage and cellular stress. There is increasing evidence that chymase in mast cells is one of the key factors contributing to tissue remodeling and CVD progression. Activated mast cells play an important role in wound healing and inflammatory elimination, such as wound fibrosis, angiogenesis and myocardial remodeling (Miyazaki et al, Pharmacol. Ther,112(2006), 668-676; Shiota et al, J.Hypertens,21(2003), 1823-1825). An increase in the number of mast cells is observed in the case of heart failure, myocardial infarction and ischemia, in the case of atherosclerotic plaques and abdominal aortic aneurysms in humans (Kovanen et al, Circulation,92(1995), 1084-. In asthma and chronic obstructive pulmonary disease, chymase-positive mast cells play an important role in airway vascular remodeling. It has now been found that an increased number of mast cells is found in endobronchial biopsies of asthmatic patients (Zanini et al, J.allergy Clin Immunol,120(2007), 329-. Furthermore, chymase is also suspected to be one of the causes of various renal disorders such as diabetic nephropathy and polycystic kidney disease (Huang et al, J.Am.Soc.Nephrol,14(7), (2003), 1738-.

Chymase is mainly involved in the production of angiotensin II in the heart, arterial walls and lungs. Early studies by Cleveland clinic researchers demonstrated for the first time the role of chymase as an Ang II (angiotensin II) forming enzyme (Urata H et al, J.biol.chem,1990,265(36): 22348-57). During the past decades, several studies have demonstrated and expanded the importance of chymase as a synthetase in the Ang II production pathway (Chandrasekharan UM et al, Science,1996,271(5248): 502-5). Subsequent studies on Ang- (1-12) treatment of human and rodent hearts have shown that enzymes that directly form Ang-II, whether Ang I or Ang- (1-12), are dominated by chymase (Ahmad S et al, j.am. soc. hypertens, 20137 (2): 128-36). Ang II (angiotensin II) is an effector molecule that effects blood pressure regulation and water and electrolyte balance control, primarily by acting on multiple target receptors on the cell surface nuclear membrane of the vessel wall, renal tubules, glomeruli, adrenal glands. When angiotensin II is combined with angiotensin receptor, it can cause corresponding physiological effects, including constriction of systemic arteriole and vein, increase of blood pressure and increase of blood volume in heart; stimulates the adrenal glands to synthesize and release aldosterone. Therefore, inhibition of chymase activation can reduce angiotensin production, and control vascular constriction and blood pressure elevation to some extent.

The possibility of treating various cardiovascular diseases with chymase inhibitors has been demonstrated in studies in a number of animal experiments. For example, chymase inhibitors are useful for treating myocardial infarction (Jin et al, pharmacol. exp. ther,309(2004),409-417), and experiments have shown that when ligation of the coronary arteries in dogs causes ventricular arrhythmia, the production of angiotensin II in the heart is promoted and chymase activity is enhanced. In recent years, Bayer company is developing an oral small molecule chymotrypsin inhibitor BAY-1142524 for treating heart failure and diabetic nephropathy, and preclinical results show that the compound can improve the cardiac function of hamsters after myocardial infarction. The clinical first-stage results also show the good safety, tolerability and pharmacokinetic properties of BAY-1142524 in healthy subjects. At present, Bayer company has carried out a second-stage clinical experiment of BAY-1142524 for treating diabetic nephropathy, and further verifies the curative effect and safety of the novel chymotrypsin inhibitor.

Thus, chymase inhibition constitutes an effective method for treating cardiovascular disorders, inflammation, allergic disorders, and various fibrotic disorders.

Disclosure of Invention

The invention provides a novel substituted nitrogen-containing bicyclic compound serving as a chymotrypsin-like inhibitor, which is used for preventing, treating or relieving heart failure or myocardial infarction and other related cardiovascular diseases. Experiments show that the substituted nitrogen-containing bicyclic compound has stable property, good safety, good pharmacodynamics and pharmacokinetic properties, such as good chymotrypsin-like inhibition activity, good bioavailability and/or good metabolic stability. Therefore, the compound has good clinical application prospect.

The invention also provides a method for preparing the compound, a pharmaceutical composition containing the compound and application of the compound and/or the pharmaceutical composition of the compound in preparing medicaments.

In one aspect, the invention relates to a compound of formula (I), or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof,

wherein: each A,R⁰、t、E、R¹And R²Have the meaning as described in the present invention.

In some embodiments, R ²Is composed of

Wherein R is⁵And m has the meaning described in the present invention.

In some embodiments, m is 0, 1, 2, 3, or 4.

In some embodiments, R²Is composed of

Wherein R is⁵Have the meaning as described in the present invention.

In some embodiments, the compound of the present invention, which may be a compound of formula (IIa) or formula (IIb) or formula (IIc), or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt, or prodrug thereof of a compound of formula (IIa) or formula (IIb) or formula (IIc),

wherein: each A, R⁰、t、E、R¹And R⁵Have the meaning as described in the present invention.

In some embodiments, E is a bond, -CH₂-or-C (═ O) -. Preferably, E is-C (═ O) -.

In some embodiments, ring a is a 5-6 membered heteroaromatic ring or a benzene ring.

In some embodiments, ring a is pyrrole, pyrazole, imidazole, triazole, tetrazole, furan, thiophene, thiazole, oxazole, pyridine, pyrimidine, pyrazine, pyridazine, or benzene. Preferably, ring a is pyrazole, pyridine or benzene.

In some embodiments, each R is⁰Independently H, D, halogen, C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy, halo C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C _6-10Aryl, 5-12 atom heteroaryl, CN, NO₂、-OR^a、-C(O)R^a1、-C(O)NR^a2R^b、-C(O)OR^a、-NR^a2R^b、-NR^a3C(O)R^a1、-NR^a3C(O)OR^a、-NR^a3C(O)NR^a2R^b、-SO₂R^a1、-SO₂NR^a2R^bor-NR^a3SO₂NR^a2R^bWherein said C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy, halo C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl and heteroaryl of 5 to 12 atoms are independently unsubstituted or substituted by 1, 2, 3, 4 or 5R^mSubstituted; r^a、R^a1、R^a2、R^a3、R^bAnd R^mEach independently having the meaning described in the present invention.

In some embodiments, t is 0, 1, 2, 3, or 4.

In some embodiments, R^a、R^a1、R^a2、R^a3And R^bEach independently is H, D, C_1-6Alkyl radical, C_1-6Haloalkyl, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms.

In some embodiments, each R is^mIndependently D, halogen, CN, NO₂、OH、NH₂、C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy or halo C_1-6An alkoxy group.

In some embodiments, R¹Is composed of

Wherein R is³And R⁴Have the meaning as described in the present invention.

In some embodiments, R³is-NRⁿ-, -O-, -S-or-CR^cR^d-; wherein R isⁿ、R^cAnd R^dEach independently having the meaning described in the present invention.

In some embodiments, RⁿIs H, D, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Haloalkyl, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C _6-10Aryl or heteroaryl of 5 to 12 atoms.

In some embodiments, R^cAnd R^dEach independently is H, D, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Haloalkyl, C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms.

In some embodiments, R⁴Is H, D, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Haloalkyl, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms.

In some embodiments, each R is⁵Independently H, D, halogen, NO₂、CN、OH、NH₂、C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy, halo C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms.

In some embodiments, each R is⁰Independently H, D, F, Cl, Br, C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy, halo C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl, heteroaryl consisting of 5-10 atoms, CN, NO₂、-OR^a、-C(O)R^a1、-C(O)NR^a2R^b、-C(O)OR^a、-NR^a2R^b、-NR^a3C(O)R^a1、-NR^a3C(O)OR^a、-NR^a3C(O)NR^a2R^b、-SO₂R^a1、-SO₂NR^a2R^bor-NR^a3SO₂NR^a2R^bWherein said C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy, halo C_1-4Alkoxy radical, C_3-6Cycloalkyl, a heterocyclic group consisting of 3 to 6 atoms, C _6-10Aryl and heteroaryl of 5 to 10 atoms independently unsubstituted or substituted by 1, 2, 3 or 4R^mIs substituted wherein R is^a、R^a1、R^a2、R^a3、R^bAnd R^mEach independently having the meaning described in the present invention.

In some embodiments, R^a、R^a、R^a1、R^a2、R^a3And R^bEach independently is H, D, C_1-4Alkyl radical, C_1-4Haloalkyl, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms.

In some embodiments, each R is^mIndependently D, halogen, CN, NO₂、OH、NH₂、C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy or halo C_1-4An alkoxy group.

In some embodiments, RⁿIs H, D, C_1-4Alkyl radical, C_2-4Alkenyl radical, C_2-4Alkynyl, C_1-4Haloalkyl, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms.

In some embodiments, R^cAnd R^dEach independently is H, D, C_1-4Alkyl radical, C_2-4Alkenyl radical, C_2-4Alkynyl radical、C_1-4Haloalkyl, C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms.

In some embodiments, R⁴Is H, D, C_1-4Alkyl radical, C_2-4Alkenyl radical, C_2-4Alkynyl, C_1-4Haloalkyl, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms.

In some embodiments, each R is⁵Independently H, D, halogen, NO₂、CN、OH、NH₂、C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy, halo C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms.

In some embodiments, each R is⁰Independently H, D, F, Cl, Br, NO₂、CN、OH、NH₂Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CF₃、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy, trifluoroethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, etcTriazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, -OR^a、-C(O)R^a1、-C(O)NR^a2R^b、-C(O)OR^a、-NR^a2R^b、-NR^a3C(O)R^a1、-NR^a3C(O)OR^a、-NR^a3C(O)NR^a2R^b、-SO₂R^a1、-SO₂NR^a2R^bor-NR^a3SO₂NR^a2R^bWherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH ₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, difluoroethoxy, trifluoroethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl are unsubstituted or substituted with 1, 2, 3, 4, or 5R^mWherein R is^a、R^a1、R^a2、R^a3、R^bAnd R^mEach independently has the meaning described in the present invention.

In some embodiments, R^a、R^a1、R^a2、R^a3And R^bEach independently is H, D, methylEthyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CHF₂、-CF₃、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.

In some embodiments, each R is^mIndependently D, F, Cl, Br, NO₂、CN、OH、NH₂Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CF₃、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy or trifluoroethoxy.

In some embodiments, RⁿH, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CHF₂、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Vinyl, propenyl, allyl, ethynyl, propargyl, 1-propynyl, 1-alkynbutyl, 2-alkynylbutyl, 3-alkynylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl.

In some embodiments, R^cAnd R^dEach independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH ₂F、-CHF₂、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Vinyl, propenyl, allyl, ethynyl, propargyl, 1-propynyl, 1-alkynbutyl, 2-alkynylbutyl, 3-alkynylbutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, or pyridazinyl.

In some embodiments, R⁴H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl and isobutylSec-butyl, tert-butyl, -CH₂F、-CHF₂、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Vinyl, propenyl, allyl, ethynyl, propargyl, 1-propynyl, 1-alkynbutyl, 2-alkynylbutyl, 3-alkynylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl.

In some embodiments, each R is⁵Independently H, D, F, Cl, Br, NO₂、CN、OH、NH₂Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CF₃、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy, trifluoroethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl,Tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, or pyridazinyl.

In some embodiments, the compounds of the present invention have one of the following structures or stereoisomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs thereof of the compounds having one of the following structures:

in another aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention; optionally, it further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or any combination thereof.

In some embodiments, the pharmaceutical composition according to the invention further comprises one or more additional active ingredients selected from the group consisting of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinase inhibitors, matrix metalloproteinase inhibitors, soluble guanylate cyclase stimulators and activators, and phosphodiesterase inhibitors.

In one aspect, the invention relates to the use of a compound according to the invention or a pharmaceutical composition according to the invention for the preparation of a medicament for the treatment or prevention of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal failure, renal disease, fibrotic disorders of internal organs or dermal fibrosis.

In another aspect, the invention relates to methods for the preparation, isolation and purification of compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc).

Biological test results show that the compound has good activity of inhibiting chymotrypsin-like enzyme, can be used as a better chymotrypsin-like enzyme inhibitor, and has potential efficacy of preventing the occurrence and the progress of diseases.

Any embodiment of any aspect of the invention may be combined with other embodiments, as long as they do not contradict. Furthermore, in any embodiment of any aspect of the invention, any feature may be applicable to that feature in other embodiments, so long as they do not contradict.

The foregoing merely summarizes certain aspects of the invention and is not intended to be limiting. These and other aspects will be more fully described below. All references in this specification are incorporated herein by reference in their entirety. When the disclosure of the present specification differs from the cited documents, the disclosure of the present specification controls.

Definitions and general terms

Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated by the accompanying structural and chemical formulas. The invention is intended to cover alternatives, modifications and equivalents, which may be included within the scope of the invention as defined by the appended claims. One skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated documents, patents, and similar materials differ or contradict this application (including but not limited to defined terminology, application of terminology, described techniques, and the like), this application controls.

It will be further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

The following definitions as used herein should apply unless otherwise indicated. For the purposes of the present invention, the chemical elements are in accordance with CAS version of the periodic Table of the elements, and with handbook of chemistry and Physics, 75 th edition, 1994. In addition, general principles of Organic Chemistry can be referred to as described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausaltito: 1999, and "March's Advanced Organic Chemistry" by Michael B.Smith and Jerry March, John Wiley & Sons, New York:2007, the entire contents of which are incorporated herein by reference.

In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.

The articles "a," "an," and "the" as used herein are intended to include "at least one" or "one or more" unless otherwise indicated or clearly contradicted by context. Thus, as used herein, the articles refer to one or to more than one (i.e., to at least one) of the objects. For example, "a component" refers to one or more components, i.e., there may be more than one component contemplated for use or use in embodiments of the described embodiments.

The term "stereoisomers" refers to compounds having the same chemical structure, but differing in the arrangement of atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis/trans isomers), atropisomers, and the like.

The term "chiral molecule" is a molecule having the property of not overlapping its mirror image; and "achiral molecule" refers to a molecule that can overlap with its mirror image.

The term "enantiomer" refers to two isomers of a compound that are not overlapping but are in mirror image relationship to each other.

The term "racemate" or "racemic mixture" refers to an equimolar mixture of two enantiomers lacking optical activity.

The term "diastereomer" refers to stereoisomers having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may be separated by high resolution analytical procedures such as electrophoresis and chromatography, e.g., HPLC.

The stereochemical definitions and rules used in the present invention generally follow the general definitions of S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E.and Wilen, S, "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc, New York, 1994.

Many organic compounds exist in an optically active form, i.e., they have the ability to rotate the plane of plane polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to denote the absolute configuration of a molecule with respect to one or more of its chiral centers. The prefixes d and l or (+) and (-) are the symbols used to specify the rotation of plane polarized light by the compound, where (-) or l indicates that the compound is left-handed. Compounds prefixed with (+) or d are dextrorotatory. A particular stereoisomer is an enantiomer and a mixture of such isomers is referred to as an enantiomeric mixture. A50: 50 mixture of enantiomers is referred to as a racemic mixture or racemate, which may occur when there is no stereoselectivity or stereospecificity in the chemical reaction or process.

Any asymmetric atom (e.g., carbon, etc.) of a compound disclosed herein can exist in racemic or enantiomerically enriched forms, such as the (R) -, (S) -or (R, S) -configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R) -or (S) -configuration.

Depending on the choice of starting materials and methods, the compounds of the invention may exist as one of the possible isomers or as mixtures thereof, for example as racemates and diastereomeric mixtures (depending on the number of asymmetric carbon atoms). Optically active (R) -or (S) -isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl group, the substituents of the cycloalkyl group may have cis or trans configuration.

Any resulting mixture of stereoisomers may be separated into pure or substantially pure geometric isomers, enantiomers, diastereomers, depending on differences in the physicochemical properties of the components, for example, by chromatography and/or fractional crystallization.

The racemates of any of the resulting end products or intermediates can be resolved into the optical enantiomers by known methods using methods familiar to those skilled in the art, e.g., by separation of the diastereomeric salts obtained. The racemic product can also be separated by chiral chromatography, e.g., High Performance Liquid Chromatography (HPLC) using a chiral adsorbent. In particular, Enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al, Enantiomers, racemes and solutions (Wiley Interscience, New York, 1981); principles of Asymmetric Synthesis (2)^nd Ed.Robert E.Gawley,Jeffrey Aube,Elsevier,Oxford,UK,2012)；Eliel,E.L.Stereochemistry of Carbon Compounds(McGraw-Hill,NY,1962)；Wilen,S.H.Tables of Resolving Agents and Optical Resolutions p.268(E.L.Eliel,Ed.,Univ.of Notre Dame Press,Notre Dame,IN 1972)；Chiral Separation Techniques:APractical Approach(Subramanian,G.Ed.,Wiley-VCH Verlag GmbH&Co.KGaA,Weinheim,Germany,2007)。

The term "tautomer" or "tautomeric form" refers to structural isomers having different energies that can be interconverted by a low energy barrier (low energy barrier). If tautomerism is possible (e.g., in solution), then the chemical equilibrium of the tautomer can be reached. For example, proton tautomers (also known as proton transfer tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization.

"pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or complication commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.

The term "optionally substituted with … …" is used interchangeably with the term "unsubstituted or substituted with … …", i.e., the structure is unsubstituted or substituted with one or more substituents as described herein.

In general, the term "substituted" means that one or more hydrogen atoms in a given structure or group are replaced with a particular substituent. Unless otherwise indicated, a substituent may be substituted at any reasonable position in the group that it can substitute. When more than one position in a given formula can be substituted with one or more particular substituents selected from the group, then the substituents may be substituted identically or differently at each of the possible positions in the formula.

The term "unsubstituted" means that the specified group carries no substituents.

In addition, unless otherwise explicitly indicated, the descriptions of the terms "… independently" and "… independently" and "… independently" used in the present invention are interchangeable, and should be understood in a broad sense, which means that the specific items expressed between the same symbols do not affect each other in different groups, or that the specific items expressed between the same symbols in the same groups do not affect each other.

The term "subject" as used herein refers to an animal. Typically the animal is a mammal. Subjects, e.g., also primates (e.g., humans, males or females), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc. In certain embodiments, the subject is a primate. In other embodiments, the subject is a human.

The term "patient" as used herein refers to humans (including adults and children) or other animals. In some embodiments, "patient" refers to a human.

The term "comprising" is open-ended, i.e. includes the elements indicated in the present invention, but does not exclude other elements.

In the various parts of this specification, substituents of the disclosed compounds are disclosed in terms of group type or range. It is specifically intended that the invention includes each and every independent subcombination of the various members of these groups and ranges. For example, the term "C₁-C₆Alkyl "means in particular independently disclosed methyl, ethyl, C₃Alkyl radical, C₄Alkyl radical, C₅Alkyl and C₆An alkyl group.

The term "D" denotes a single deuterium atom.

The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).

The term "alkyl" or "alkyl group" as used herein, denotes a saturated straight or branched chain monovalent hydrocarbon radical containing 1 to 20 carbon atoms. In one embodiment, the alkyl group contains 1-6 carbon atoms, i.e., C_1-6An alkyl group; in another embodiment, the alkyl group contains 1-4 carbon atoms, i.e., C_1-4An alkyl group; in yet another embodiment, the alkyl group contains 1 to 3 carbon atoms, i.e., C_1-3An alkyl group. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH)₃) Ethyl group (Et, -CH)₂CH₃) N-propyl (n-Pr, -CH)₂CH₂CH₃) Isopropyl group (i-Pr, -CH (CH)₃)₂) N-butyl (n-Bu, -CH)₂CH₂CH₂CH₃) Isobutyl (i-Bu, -CH)₂CH(CH₃)₂) Sec-butyl (s-Bu, -CH (CH)₃)CH₂CH₃) Tert-butyl (t-Bu, -C (CH)₃)₃) N-pentyl (-CH)₂CH₂CH₂CH₂CH₃) 2-pentyl (-CH (CH)₃)CH₂CH₂CH₃) 3-pentyl (-CH (CH)₂CH₃)₂) 2-methyl-2-butyl (-C (CH)₃)₂CH₂CH₃) 3-methyl-2-butyl (-CH (CH)₃)CH(CH₃)₂) 2, 2-dimethylbutyl (neopentyl, -CH)₂CH(CH₃)₂CH₃) 3-methyl-1-butyl (-CH)₂CH₂CH(CH₃)₂) 2-methyl-1-butyl (-CH)₂CH(CH₃)CH₂CH₃) N-hexyl (-CH)₂CH₂CH₂CH₂CH₂CH₃) 2-hexyl (-CH (CH)₃)CH₂CH₂CH₂CH₃) 3-hexyl (-CH (CH)₂CH₃)(CH₂CH₂CH₃) 2-methyl-2-pentyl (-C (CH))₃)₂CH₂CH₂CH₃) 3-methyl-2-pentyl (-CH (CH)₃)CH(CH₃)CH₂CH₃) 4-methyl-2-pentyl (-CH (CH)₃)CH₂CH(CH₃)₂) 3-methyl-3-pentyl (-C (CH)₃)(CH₂CH₃)₂) 2-methyl-3-pentyl (-CH (CH)₂CH₃)CH(CH₃)₂) 2, 3-dimethyl-2-butyl (-C (CH) ₃)₂CH(CH₃)₂) 3, 3-dimethyl-2-butyl (-CH (CH)₃)C(CH₃)₃) N-heptyl, n-octyl, and the like.

The term "alkenyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e. one carbon-carbon sp²Double bonds, which include the positioning of "cis" and "trans", or the positioning of "E" and "Z". Examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl (propenyl, -CH ═ CH-CH)₃)，2-Propenyl group (allyl, -CH)₂-CH＝CH₂) And so on.

The term "alkynyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein there is at least one site of unsaturation, i.e. a carbon-carbon sp triple bond. In some embodiments, alkynyl groups contain 2-8 carbon atoms; in other embodiments, alkynyl groups contain 2-6 carbon atoms; in still other embodiments, alkynyl groups contain 2-4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (-C.ident.CH), propargyl (-CH)₂C.ident.CH), 1-propynyl (-C.ident.C-CH)₃) 1-alkynylbutyl (-CH)₂CH₂C ≡ CH), 2-alkynylbutyl (-CH)₂C≡CCH₃) 3-alkynylbutyl (-C [ identical to ] CCH₂CH₃) And so on.

The term "alkoxy" means an alkyl group attached to the rest of the molecule through an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1 to 12 carbon atoms. In some embodiments, alkoxy groups contain 1 to 6 carbon atoms; in other embodiments, the alkoxy group contains 1 to 4 carbon atoms; in still other embodiments, alkoxy groups contain 1-3 carbon atoms.

Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH)₃) Ethoxy (EtO, -OCH)₂CH₃) 1-propoxy (n-PrO, n-propoxy, -OCH)₂CH₂CH₃) 2-propoxy (i-PrO, i-propoxy, -OCH (CH)₃)₂) 1-butoxy (n-BuO, n-butoxy, -OCH)₂CH₂CH₂CH₃) 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH)₂CH(CH₃)₂) 2-butoxy (s-BuO, s-butoxy, -OCH (CH)₃)CH₂CH₃) 2-methyl-2-propoxy (t-BuO, t-butoxy, -OC (CH)₃)₃) 1-pentyloxy (n-pentyloxy, -OCH)₂CH₂CH₂CH₂CH₃) 2-pentyloxy (-OCH (CH))₃)CH₂CH₂CH₃) 3-pentyloxy (-OCH (CH))₂CH₃)₂) 2-methyl-2-butoxy (-OC (CH))₃)₂CH₂CH₃) 3-methyl-2-butoxy (-OCH (CH)₃)CH(CH₃)₂) 3-methyl-l-butoxy (-OCH)₂CH₂CH(CH₃)₂) 2-methyl-l-butoxy (-OCH)₂CH(CH₃)CH₂CH₃) And so on.

The term "haloalkoxy" denotes an alkoxy group substituted with one or more halogen atoms, wherein alkoxy has the meaning described herein. Examples include, but are not limited to, difluoromethoxy (-OCHF)₂) Trifluoromethoxy (-OCF)₃) Difluoroethoxy (e.g. -OCH)₂CHF₂Etc.), trifluoroethoxy (e.g., -OCH)₂CF₃Etc.), etc.

The term "haloalkyl" denotes an alkyl group substituted with one or more halogen atoms, wherein alkyl has the meaning described herein. In some of these embodiments, the haloalkyl group contains 1 to 12 carbon atoms; in still other embodiments, the haloalkyl group contains 1 to 10 carbon atoms; in still other embodiments, the haloalkyl group contains 1 to 8 carbon atoms; in still other embodiments, the haloalkyl group contains 1 to 6 carbon atoms; in other embodiments, the haloalkyl group contains 1 to 4 carbon atoms, and in other embodiments, the haloalkyl group contains 1 to 3 carbon atoms. Examples include, but are not limited to, difluoromethyl, trifluoromethyl, trifluoroethyl (e.g., -CH) ₂CF₃Etc.), etc.

The term "cycloalkyl" denotes a saturated monocyclic, bicyclic or tricyclic ring system containing from 3 to 12 ring carbon atoms. In some embodiments, cycloalkyl groups contain 3 to 10 ring carbon atoms, e.g., C_3-10A cycloalkyl group; in other embodiments, cycloalkyl groups contain 3 to 8 ring carbon atoms, e.g., C_3-8A cycloalkyl group; in still other embodiments, cycloalkyl groups contain 3-6 ring carbon atoms, e.g., C_3-6A cycloalkyl group. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexylMesityl, cycloheptyl, cyclooctyl, and the like. Wherein, as described in the present invention, C_3-8Cycloalkyl radicals including C_3-6A cycloalkyl group; said C_3-6Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The terms "heterocyclyl" and "heterocycle" are used interchangeably herein and refer to a mono-, bi-or tricyclic ring system containing 3 to 12 ring atoms, which is monovalent or multivalent, saturated or partially unsaturated, and non-aromatic, wherein at least one ring atom is selected from nitrogen, sulfur, and oxygen atoms. Unless otherwise specified, a heterocyclic group may be carbon-or nitrogen-based, and-CH₂-the group may optionally be replaced by-C (═ O) -. The sulfur atom of the ring may optionally be oxidized to the S-oxide. The nitrogen atom of the ring may optionally be oxidized to an N-oxygen compound. Heterocyclyl includes saturated heterocyclyl (i.e., heterocycloalkyl) and partially unsaturated heterocyclyl. Examples of heterocyclyl groups include, but are not limited to, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiazolidinyl, pyrazolidinyl, oxazolidinyl, imidazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, or morpholinyl, and the like. As described herein, the heterocyclyl group may consist of 3 to 8 atoms or 3 to 6 atoms, optionally selected from C, N, O or S and at least one atom being N, O or S; wherein the heterocyclic group consisting of 3 to 8 atoms includes a heterocyclic group consisting of 3 to 6 atoms; the heterocyclic group consisting of 3 to 6 atoms includes a heterocyclic group consisting of 3 to 5 atoms. Specifically, the heterocyclic group consisting of 3 to 6 atoms includes, but is not limited to, ethylene oxide, aziridinyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiazolidinyl, pyrazolidinyl, pyrazolinyl, oxazolidinyl, imidazolidinyl, piperidinyl, piperazinyl, morpholinyl, and the like.

The term "s-atom composed", where s is an integer, typically describes the number of ring-forming atoms in a molecule in which the number of ring-forming atoms is s. For example, piperidinyl is a heterocycloalkyl group of 6 atoms, and 1,2,3, 4-tetrahydronaphthyl is a carbocyclyl group of 10 atoms.

The term "unsaturated" as used herein means that the group contains one or more unsaturations.

The term "heteroatom" refers to O, S, N, P and Si, including N, S and any oxidation state form of P; primary, secondary, tertiary amines and quaternary ammonium salt forms; or a form in which a hydrogen on a nitrogen atom in the heterocycle is substituted, for example, N (like N in 3, 4-dihydro-2H-pyrrolyl), NH (like NH in pyrrolidinyl) or NR (like NR in N-substituted pyrrolidinyl, wherein R is any suitable substituent).

The term "aryl" denotes monocyclic, bicyclic and tricyclic carbon ring systems containing 6 to 14 ring atoms, or 6 to 12 ring atoms, or 6 to 10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system contains 3 to 7 atoms in the ring and one or more attachment points to the rest of the molecule. The term "aryl" may be used interchangeably with the term "aromatic ring". Examples of the aryl group may include phenyl, naphthyl and anthracenyl. Unless otherwise stated, the group "C _6-10Aryl "represents an aryl group containing from 6 to 10 ring carbon atoms.

The term "heteroaryl" denotes monocyclic, bicyclic and tricyclic ring systems containing 5 to 12 ring atoms, or 5 to 10 ring atoms, or 5 to 6 ring atoms, wherein at least one ring is aromatic and at least one ring contains 1, 2, 3 or 4 ring heteroatoms selected from nitrogen, oxygen, sulfur, and wherein the heteroaryl has one or more attachment points to the rest of the molecule. when-CH is present in the heteroaryl radical₂When the radical is-CH₂-a group may optionally be replaced by-C (═ O) -. Unless otherwise indicated, the heteroaryl group may be attached to the rest of the molecule (e.g., the main structure in the general formula) via any reasonable site (which may be C in CH, or N in NH). The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound". Examples of heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl and the like. In some embodiments, heteroaryl is 5-10 atom consisting of heteroaryl, meaning that heteroaryl contains 1-9 atomsA ring carbon atom and 1, 2, 3 or 4 ring heteroatoms selected from O, S and N; in other embodiments, heteroaryl is 5-6 atom heteroaryl, meaning that heteroaryl contains 1-5 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from O, S and N, examples of 5-6 atom heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, and the like.

The term "protecting group" or "PG" refers to a substituent that, when reacted with other functional groups, is generally used to block or protect a particular functionality. For example, "amino protecting group" means a substituent attached to an amino group to block or protect the functionality of the amino group in a compound, and suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC ), benzyloxycarbonyl (CBZ ) and 9-fluorenylmethoxycarbonyl (Fmoc). Similarly, "hydroxy protecting group" refers to the functionality of a substituent of a hydroxy group to block or protect the hydroxy group, and suitable protecting groups include trialkylsilyl, acetyl, benzoyl and benzyl. "carboxy protecting group" refers to the functionality of a substituent of a carboxy group to block or protect the carboxy group, and typical carboxy protecting groups include-CH₂CH₂SO₂Ph, cyanoethyl, 2- (trimethylsilyl) ethyl, 2- (trimethylsilyl) ethoxymethyl, 2- (p-toluenesulfonyl) ethyl, 2- (p-nitrobenzenesulfonyl) ethyl, 2- (diphenylphosphino) ethyl, nitroethyl, and the like. General descriptions of protecting groups can be found in the literature: greene et al, Protective Groups in Organic Synthesis, John Wiley &Sons,New York,1991and Kocienski et al.,Protecting Groups,Thieme,Stuttgart,2005。

The term "prodrug", as used herein, represents a compound that is converted in vivo to a compound of formula (I) or formula (IIa) or formula (IIb) or formula (IIc). Such conversion is effected by hydrolysis of the prodrug in the blood or by enzymatic conversion to the parent structure in the blood or tissue. The prodrug compound of the invention can be ester, and the ester can be phenyl ester of prodrug in the prior inventionClass i, aliphatic (C)_1-24) Esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound of the present invention contains a hydroxy group, i.e., it can be acylated to provide the compound in prodrug form. Other prodrug forms include phosphate esters, such as those obtained by phosphorylation of a hydroxyl group on the parent. For a complete discussion of prodrugs, reference may be made to the following: T.Higuchi and V.Stella, Pro-drugs as Novel Delivery Systems, Vol.14of the A.C.S.Symphosis Series, Edward B.Roche, ed., Bioreversible Carriers in Drug designs, American Pharmaceutical Association and Pergamon Press,1987, J.Rautio et al, Prodrugs in Design and Clinical Applications, Nature Review Delivery, 2008,7,255 and 270, S.J.Herer et al, Prodrugs of pharmaceuticals and pharmaceuticals, Journal of chemical Chemistry,2008,51,2328 and 5.

"metabolite" refers to the product of a particular compound or salt thereof obtained by metabolism in vivo. Metabolites of a compound can be identified by techniques well known in the art, and its activity can be characterized by assay methods as described herein. Such products may be obtained by administering the compound by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.

As used herein, "pharmaceutically acceptable salts" refer to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as are: berge et al, describe pharmacological acceptable salts in detail in j. pharmaceutical Sciences, 1977, 66: 1-19. Pharmaceutically acceptable non-toxic acid forming salts include, but are not limited to, inorganic acid salts formed by reaction with amino groups such as hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, and organic acid salts such as acetate, oxalate, maleate, Tartrate, citrate, succinate, malonate, or by other methods described in the literature such as ion exchange. Other pharmaceutically acceptable salts include adipates, alginates, ascorbates, aspartates, benzenesulfonates, benzoates, bisulfates, borates, butyrates, camphorates, camphorsulfonates, cyclopentylpropionates, digluconates, dodecylsulfates, ethanesulfonates, formates, fumarates, glucoheptonates, glycerophosphates, gluconates, hemisulfates, heptanoates, hexanoates, hydroiodides, 2-hydroxy-ethanesulfonates, lactobionates, lactates, laurates, malates, malonates, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, palmitates, pamoates, pectinates, persulfates, 3-phenylpropionates, picrates, pivalates, propionates, stearates, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts obtained with appropriate bases include alkali metals, alkaline earth metals, ammonium and N ⁺(C_1-4Alkyl radical)₄A salt. The present invention also contemplates quaternary ammonium salts formed from compounds containing groups of N. Water-soluble or oil-soluble or dispersion products can be obtained by quaternization. Alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include suitable, non-toxic ammonium, quaternary ammonium salts and amine cations resistant to formation of counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C₁-C₈Sulfonates and aromatic sulfonates.

"nitroxide" in the context of the present invention means that when a compound contains several amine functional groups, 1 or more than 1 nitrogen atom can be oxidized to form an N-oxide. Specific examples of N-oxides are N-oxides of tertiary amines or N-oxides of nitrogen-containing heterocyclic nitrogen atoms. The corresponding amines can be treated with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid) to form the N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4 th edition, Jerry March, pages). In particular, the N-oxide may be prepared by the method of L.W.Deady (Syn.Comm.1977,7,509-514) in which an amine compound is reacted with m-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.

"solvate" of the present invention refers to an association of one or more solvent molecules with a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, ethanolamine, or mixtures thereof. The term "hydrate" refers to an association of solvent molecules with water.

When the solvent is water, the term "hydrate" may be used. In one embodiment, a molecule of a compound of the present invention may be associated with a molecule of water, such as a monohydrate; in another embodiment, one molecule of the compound of the present invention may be associated with more than one molecule of water, such as a dihydrate; in yet another embodiment, one molecule of the compound of the present invention may be associated with less than one molecule of water, such as a hemihydrate. It should be noted that the hydrates of the present invention retain the biological effectiveness of the compound in its non-hydrated form.

The term "treating" any disease or condition, in some embodiments refers to ameliorating the disease or condition (i.e., slowing or arresting or reducing the development of the disease or at least one clinical symptom thereof). In other embodiments, "treating" or "treatment" refers to moderating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" or "treatment" refers to modulating the disease or disorder, either physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a parameter of the body), or both. In other embodiments, "treating" or "treatment" refers to preventing or delaying the onset, occurrence, or worsening of a disease or disorder.

The term "prevent" or "prevention" refers to a reduction in the risk of acquiring a disease or disorder (i.e., arresting the development of at least one clinical symptom of a disease in a subject that may be facing or predisposed to facing such a disease, but does not yet experience or exhibit symptoms of the disease).

The term "cardiovascular disease" refers to a general term for cardiovascular and cerebrovascular diseases, and describes ischemic or hemorrhagic diseases of heart, brain and systemic tissues of patients due to hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. Such as acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina, myocardial ischemia, myocardial infarction, shock, atherosclerosis, cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, preeclampsia, inflammatory cardiovascular diseases, peripheral and cardiovascular diseases, peripheral perfusion disorders, pulmonary hypertension, coronary and peripheral arterial spasm, thrombosis, thromboembolic diseases, edema development (e.g., pulmonary edema, cerebral edema, renal edema, or edema associated with heart failure) and restenosis (e.g., restenosis following thrombolytic therapy, Percutaneous Transluminal Angioplasty (PTA), percutaneous coronary angioplasty (PTCA), cardiac transplantation and bypass surgery), and microvascular and macrovascular injury (vasculitis), reperfusion injury, arterial and venous thrombosis, Microalbuminuria, myocardial insufficiency, endothelial dysfunction, peripheral and cardiovascular disease, peripheral perfusion dysfunction, heart failure-associated edema, elevated levels of fibrinogen and low-density LDL, and elevated concentrations of plasminogen activator/inhibitor 1 (PAI-1).

Compounds of the invention

In one aspect, the invention relates to compounds having a structure represented by formula (I), wherein the variables are as previously defined.

In some embodiments, the compound of formula (I) of the present invention can be a compound of formula (IIa), formula (IIb), or formula (IIc), wherein the variables are as defined above.

Unless otherwise specified, stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts of compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc) or prodrugs thereof are included within the scope of the present invention.

The compounds of the present disclosure may contain asymmetric or chiral centers and thus may exist in different stereoisomeric forms. The present invention contemplates that all stereoisomeric forms of the compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc), including but not limited to diastereomers, enantiomers, atropisomers and geometric (or conformational) isomers, and mixtures thereof, such as racemic mixtures, are integral to the invention.

In the structures disclosed herein, when the stereochemistry of any particular chiral atom is not specified, then all stereoisomers of that structure are contemplated as within this invention and are included as disclosed compounds in this invention. When stereochemistry is indicated by a solid wedge (solid wedge) or dashed line representing a particular configuration, then the stereoisomers of the structure are so well-defined and defined.

The compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc) may exist in different tautomeric forms, and all such tautomers, such as those described herein, are included within the scope of the present invention.

The compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc) may be present in the form of salts. In some embodiments, the salt refers to a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or the mammal being treated therewith. In other embodiments, the salt need not be a pharmaceutically acceptable salt, and may be an intermediate useful in the preparation and/or purification of a compound of formula (I) or formula (IIa) or formula (IIb) or formula (IIc) and/or in the isolation of an enantiomer of a compound of formula (I) or formula (IIa) or formula (IIb) or formula (IIc).

Pharmaceutically acceptable acid addition salts may be formed by reaction of a compound of formula (I) or formula (IIa) or formula (IIb) or formula (IIc) with an inorganic or organic acid, for example, acetate, aspartate, benzoate, benzenesulfonate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlorotheolate, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthalenesulfonate, nicotinate, nitrate, octadecanoate, oleate, oxalate, nicotinate, sulphate, nicotinate, salicylate, nicotinate, camphorate, cinnabalate, cinnabar, palmitate, pamoate, phosphate/hydrogenphosphate/dihydrogenphosphate, polypyrolactobionate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate and trifluoroacetate.

Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, sulfosalicylic acid, and the like.

Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.

Inorganic bases from which salts can be derived include, for example, ammonium salts and metals of groups I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.

Organic bases from which salts can be derived include primary, secondary and tertiary amines, and substituted amines include naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Some organic amines include, for example, isopropylamine, benzathine (benzathine), choline salts (cholinate), diethanolamine, diethylamine, lysine, meglumine (meglumine), piperazine, and tromethamine.

The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, basic or acidic moiety, by conventional chemical methods. In general, such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of the appropriate base (e.g., Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, etc.), or by reacting the free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are usually carried out in water or an organic solvent or a mixture of both. Generally, where appropriate, it is desirable to use a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile. In, for example, "Remington's Pharmaceutical Sciences", 20 th edition, Mack Publishing Company, Easton, Pa., (1985); and "handbook of pharmaceutically acceptable salts: properties, Selection and application (Handbook of Pharmaceutical Salts: Properties, Selection, and Use) ", Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002) may find some additional lists of suitable Salts.

In addition, the compounds disclosed herein, including their salts, may also be obtained in the form of their hydrates or in the form of solvents containing them (e.g., ethanol, DMSO, etc.), for their crystallization. The compounds disclosed herein may form solvates with pharmaceutically acceptable solvents (including water), either inherently or by design; thus, the present invention is intended to include both solvated and unsolvated forms.

Any formulae given herein are also intended to represent the non-isotopically enriched forms as well as the isotopically enriched forms of these compounds. Isotopically enriched compounds have the structure depicted by the formulae given herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as²H、³H、¹¹C、¹³C、¹⁴C、¹⁵N、¹⁷O、¹⁸O、¹⁸F、³¹P、³²P、³⁵S、³⁶Cl and¹²⁵I。

in another aspect, the compounds of the invention include isotopically enriched compounds as defined herein, e.g. wherein a radioisotope, e.g. is present³H、¹⁴C and¹⁸those compounds of F, or in which a non-radioactive isotope is present, e.g.²H and¹³C. the isotopically enriched compounds can be used In metabolic studies (use)¹⁴C) Reaction kinetics study (using, for example²H or³H) Detection or imaging techniques such as Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) including drug or substrate tissue distribution determination, or may be used in radiotherapy of a patient.¹⁸F-enriched compounds are particularly desirable for PET or SPECT studies. Isotopically enriched compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc) can be prepared by conventional techniques known to those skilled in the art or by the use of suitable isotopically labelled reagents in place of the original used unlabelled reagents described in the examples and preparations of this invention.

In addition, heavier isotopes are, in particular, deuterium (i.e.,²substitution of H or D) may provide certain therapeutic advantages resulting from greater metabolic stability. For example, increased in vivo half-life or decreased dosage requirements or improved therapeutic index. It is to be understood that deuterium in the present invention is to be considered as a substituent of a compound of formula (I) or formula (IIa) or formula (IIb) or formula (IIc). The concentration of such heavier isotopes, particularly deuterium, can be defined by isotopic enrichment factors. The term "isotopic enrichment factor" as used herein refers to the ratio between the isotopic and natural abundance of a given isotope. If a substituent of a compound of the invention is designated as deuterium, the compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates of the invention include those in which the crystallization solvent may be isotopically substituted, e.g. D ₂O, acetone-d₆、DMSO-d₆Those solvates of (a).

In another aspect, the invention relates to intermediates for the preparation of compounds of formula (I) or formula (IIa) or formula (IIb) or formula (IIc).

Pharmaceutical compositions, formulations and administration of the compounds of the invention

The invention provides a pharmaceutical composition, which comprises a compound shown as a formula (I) or a formula (IIa) or a formula (IIb) or a formula (IIc) or a single stereoisomer, a racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof. In one embodiment of the invention, the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, adjuvant or vehicle, and optionally other therapeutic and/or prophylactic ingredients.

Suitable carriers, adjuvants and excipients are well known to those skilled in the art and are described in detail, for example, in Ansel h.c.et al, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, philidelphia; gennaro a.r.et al, Remington: the Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins, Philadelphia; and Rowe R.C., Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago.

A method of treatment comprising administration of a compound or pharmaceutical composition of the invention, further comprising an additional therapeutic agent, wherein the other active ingredient: calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinase inhibitors, matrix metalloproteinase inhibitors, soluble guanylate cyclase stimulators and activators and phosphodiesterase inhibitors.

As used herein, "pharmaceutically acceptable excipient" means a pharmaceutically acceptable material, mixture or vehicle, which is compatible with the dosage form or pharmaceutical composition in which it is to be administered. Each excipient, when mixed, must be compatible with the other ingredients of the pharmaceutical composition to avoid interactions that would substantially reduce the efficacy of the disclosed compounds and which would result in a pharmaceutical composition that is not pharmaceutically acceptable when administered to a patient. Furthermore, each excipient must be pharmaceutically acceptable, e.g., of sufficiently high purity.

Suitable pharmaceutically acceptable excipients will vary depending on the particular dosage form selected. In addition, pharmaceutically acceptable excipients may be selected for their specific function in the composition. For example, certain pharmaceutically acceptable excipients may be selected to aid in the production of a uniform dosage form. Certain pharmaceutically acceptable excipients may be selected to aid in the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be selected to facilitate carrying or transporting a compound of the invention from one organ or portion of the body to another organ or portion of the body when administered to a patient. Certain pharmaceutically acceptable excipients may be selected that enhance patient compliance.

Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, colorants, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants and buffers. The skilled artisan will recognize that certain pharmaceutically acceptable excipients may provide more than one function, and provide alternative functions, depending on how many such excipients are present in the formulation and which other excipients are present in the formulation.

The skilled person is knowledgeable and skilled in the art to enable them to select suitable amounts of suitable pharmaceutically acceptable excipients for use in the present invention. Furthermore, there is a large amount of resources available to the skilled person, who describes pharmaceutically acceptable excipients and is used to select suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (The American Pharmaceutical Association and The Pharmaceutical Press).

For preparing pharmaceutical compositions using the compounds described herein, the pharmaceutically acceptable carrier can be a solid or liquid carrier. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. Powders and tablets may contain from about 5% to about 95% of the active ingredient. Suitable solid carriers are known in the art, for example, magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods for preparing the various compositions can be found in: gennaro (ed.), Remington's Pharmaceutical Sciences,18^th ed.,1990,Mack Publishing Company Co.,Easton,Pennsylvania。

Various carriers for The formulation of pharmaceutically acceptable compositions, and well known techniques for their preparation, are disclosed in Remington, The Science and Practice of Pharmacy,21st edition,2005, ed.D.B.Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds.J.Swarbrick and J.C.Boylan, 1988. Annu 1999, Marcel Dekker, New York, The contents of each of which are incorporated herein by reference. Except insofar as any conventional carrier is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or interacting in a deleterious manner with any other ingredient in a pharmaceutically acceptable composition, its use is contemplated as falling within the scope of the present invention.

The pharmaceutical compositions disclosed herein are prepared using techniques and methods known to those skilled in the art. Some commonly used methods in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).

Thus, in another aspect, the invention relates to a process for preparing a pharmaceutical composition comprising a compound of the present disclosure and a pharmaceutically acceptable excipient, carrier, adjuvant, vehicle or combination thereof, which process comprises admixing the ingredients. Pharmaceutical compositions comprising the disclosed compounds may be prepared by mixing, for example, at ambient temperature and atmospheric pressure.

The compounds disclosed herein are generally formulated in a dosage form suitable for administration to a patient by a desired route. For example, dosage forms include those suitable for the following routes of administration: (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets and cachets; (2) parenteral administration, such as sterile solutions, suspensions, and reconstituted powders; (3) transdermal administration, such as transdermal patches; (4) rectal administration, e.g., suppositories; (5) inhalation, such as aerosols, solutions, and dry powders; and (6) topical administration, such as creams, ointments, lotions, solutions, pastes, sprays, foams and gels.

It will also be appreciated that certain compounds of the invention may be present in free form for use in therapy or, if appropriate, in the form of a pharmaceutically acceptable derivative thereof. Some non-limiting embodiments of pharmaceutically acceptable derivatives include pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any additional adduct or derivative that upon administration to a patient in need thereof provides, directly or indirectly, a compound of the present invention or a metabolite or residue thereof.

In one embodiment, the compounds disclosed herein may be formulated in oral dosage forms. In another embodiment, the compounds disclosed herein may be formulated in an inhalation dosage form. In another embodiment, the compounds disclosed herein can be formulated for nasal administration. In yet another embodiment, the compounds disclosed herein can be formulated for transdermal administration. In yet another embodiment, the compounds disclosed herein may be formulated for topical administration.

The pharmaceutical compositions provided by the present invention may be provided as compressed tablets, milled tablets, chewable lozenges, fast-dissolving tablets, double-compressed tablets, enteric-coated tablets, sugar-coated or film-coated tablets. Enteric coated tablets are compressed tablets coated with a substance that is resistant to the action of gastric acid but dissolves or disintegrates in the intestine, thereby preventing the active ingredient from contacting the acidic environment of the stomach. Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which can help to mask unpleasant tastes or odors and prevent oxidation of the tablet. Film-coated tablets are compressed tablets covered with a thin layer or film of a water-soluble substance. Film coatings include, but are not limited to, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coatings are endowed with the same general characteristics as sugar coatings. A tabletted tablet is a compressed tablet, including a multi-layered tablet, a press coated or a dry coated tablet, prepared over more than one compression cycle.

Tablet dosage forms may be prepared from the active ingredient in powder, crystalline or granular form, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled release polymers, lubricants, diluents and/or colorants. Flavoring and sweetening agents are particularly useful in forming chewable tablets and lozenges.

The pharmaceutical composition provided by the present invention may be provided in soft or hard capsules, which may be prepared from gelatin, methylcellulose, starch or calcium alginate. The hard gelatin capsules, also known as Dry Fill Capsules (DFC), consist of two segments, one inserted into the other, thus completely encapsulating the active ingredient. Soft Elastic Capsules (SEC) are soft, spherical shells, such as gelatin shells, which are plasticized by the addition of glycerol, sorbitol or similar polyols. The soft gelatin shell may contain a preservative to prevent microbial growth. Suitable preservatives are those as described herein, including methyl and propyl parabens, and sorbic acid. The liquid, semi-solid and solid dosage forms provided by the present invention may be encapsulated in a capsule. Suitable liquid and semi-solid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides. Capsules containing such solutions may be as described in U.S. patent nos.4,328,245; 4,409,239 and 4,410,545. The capsules may also be coated as known to those skilled in the art to improve or maintain dissolution of the active ingredient.

The pharmaceutical compositions provided herein may be provided in liquid and semi-solid dosage forms, including emulsions, solutions, suspensions, elixirs and syrups. Emulsions are two-phase systems in which one liquid is dispersed throughout another in the form of globules, which can be either oil-in-water or water-in-oil. Emulsions may include pharmaceutically acceptable non-aqueous liquids and solvents, emulsifiers and preservatives. Suspensions may include a pharmaceutically acceptable suspending agent and a preservative. The aqueous alcoholic solution may comprise pharmaceutically acceptable acetals, such as di (lower alkyl) acetals of lower alkyl aldehydes, e.g. acetaldehyde diethyl acetal; and water-soluble solvents having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, hydroalcoholic solutions. Syrups are concentrated aqueous solutions of sugars, such as sucrose, and may also contain preservatives. For liquid dosage forms, for example, a solution in polyethylene glycol may be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier, such as water, for precise and convenient administration.

The pharmaceutical compositions provided herein may be formulated in any dosage form suitable for administration to a patient by inhalation, such as a dry powder, aerosol, suspension or solution composition. In one embodiment, the disclosed pharmaceutical compositions may be formulated in a dosage form suitable for inhalation administration to a patient as a dry powder. In yet another embodiment, the disclosed pharmaceutical compositions may be formulated in a dosage form suitable for inhalation administration to a patient via a nebulizer. Dry powder compositions for delivery to the lung by inhalation typically comprise a finely powdered compound of the disclosed invention and one or more finely powdered pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients that are particularly suitable for use as dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di-and polysaccharides. Fine powders may be prepared, for example, by micronization and milling. Generally, the size-reduced (e.g., micronized) compound may pass through a D of about 1 to 10 microns ₅₀Values (e.g., measured by laser diffraction).

Pharmaceutical compositions suitable for transdermal administration may be prepared as discrete patches intended to remain in intimate contact with the epidermis of the patient for a prolonged period of time. For example, the active ingredient may be delivered from a patch agent by iontophoresis, as generally described in Pharmaceutical Research,3(6),318 (1986).

Pharmaceutical compositions suitable for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For example, ointments, creams and gels may be formulated with a water or oil base, and with suitable thickeners and/or gelling agents and/or solvents. Such bases may include, water, and/or oils such as liquid paraffin and vegetable oils (e.g. arachis oil or castor oil), or solvents such as polyethylene glycols. Thickeners and gelling agents used according to the nature of the base include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, lanolin, beeswax, carbopol and cellulose derivatives, and/or glyceryl monostearate and/or non-ionic emulsifiers.

The compounds of the invention may also be conjugated to soluble polymers as targeted drug carriers. Such polymers include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol or polyoxyethylene polylysine substituted with palmitoyl residues. In addition, the disclosed compounds may be combined with a class of biodegradable polymers used in achieving controlled release of a drug, such as polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, and crosslinked or amphiphilic block copolymers of hydrogels.

The pharmaceutical compositions provided herein may be formulated in any form suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems and solid forms suitable for solution or suspension in a liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in The art of pharmaceutical Science (see Remington: The Science and Practice of Pharmacy, supra).

Pharmaceutical compositions intended for parenteral administration may include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives to inhibit microbial growth, stabilizers, solubility enhancers, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, thickening agents, pH adjusting agents, and inert gases.

The pharmaceutical compositions provided herein can be administered by rectal suppository by mixing the drug with a suitable non-irritating excipient (e.g., cocoa butter, glycerol esters of polyethylene glycol), which is solid at ordinary temperatures, and then liquefying or dissolving in the rectal cavity to release the drug. Because of the wide variation in severity of symptoms and the unique therapeutic profile of each drug, the precise mode of administration, dosage form and treatment regimen for each individual should be determined by the practitioner.

The pharmaceutical compositions provided by the present invention may be formulated in immediate or modified release dosage forms, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed release forms.

The term "therapeutically effective amount" as used herein refers to the total amount of each active component sufficient to exhibit a beneficial therapeutic effect. For example, an amount sufficient to treat, cure or alleviate the symptoms of the disease is administered or allowed to equilibrate in the body. The effective amount required for a particular treatment regimen will depend on a variety of factors including the condition being treated, the severity of the condition, the activity of the particular drug employed, the mode of administration, the clearance rate of the particular drug, the duration of the treatment, the drug combination, the age, body weight, sex, diet and patient health, etc. Other factors that may be considered in The art for a "therapeutically effective amount" are described in Gilman et al, eds., Goodman And Gilman's: The Pharmacological Bases of Therapeutics,8^thed.,Pergamon Press,1990；Remington's Pharmaceutical Sciences,17^th ed.,Mack Publishing Company,Easton,Pa.,1990。

One skilled in the art (e.g., an attending physician, pharmacist, or other technician) can readily determine the appropriate dosage of a compound of the present invention to be administered to a patient and will vary with the patient's health, age, weight, frequency of administration, use of other active ingredients, and/or the indication of the compound being administered. The dosage of the compounds of the present invention may range from about 0.001 to 500mg/kg body weight/day. In some embodiments, the amount of active compound in a unit dose of a formulation may be varied or adjusted depending on the particular application. In other embodiments, for oral administration, a suggested typical daily dosing regimen may range from about 1 mg/day to about 500 mg/day, giving two to four divided doses.

The term "administering" refers to providing a therapeutically effective amount of a drug to an individual by means including oral, sublingual, intravenous, subcutaneous, transdermal, intramuscular, intradermal, intrathecal, epidural, intraocular, intracranial, inhalation, rectal, vaginal, and the like. The administration forms include ointments, lotions, tablets, capsules, pills, dispersible powders, granules, suppositories, pellets, troches, injections, sterile or non-aqueous solutions, suspensions, emulsions, patches and the like. The active ingredient is compounded with non-toxic pharmaceutically acceptable carrier (such as glucose, lactose, gum arabic, gelatin, mannitol, starch paste, magnesium trisilicate, pulvis Talci, corn starch, keratin, silica gel, potato starch, urea, dextran, etc.).

The preferred route of administration will vary with clinical characteristics, the dosage will necessarily vary depending upon the condition of the patient being treated, and the physician will determine the appropriate dosage for the individual patient. The therapeutically effective amount per unit dose depends on body weight, physiology and the selected vaccination regimen. The weight of the compound per unit dose, excluding the weight of the carrier (vehicle included in the drug), refers to the weight of the compound per administration.

The pharmaceutical compositions provided herein may be formulated for single or multiple dose administration. The single dose formulations are packaged in ampoules, vials or syringes. The multi-dose parenteral formulation must contain a bacteriostatic or fungistatic concentration of the antimicrobial agent. All parenteral formulations must be sterile, as is known and practiced in the art.

The pharmaceutical compositions provided by the present invention may be co-formulated with other active ingredients that do not impair the intended therapeutic effect, or with substances that supplement the intended effect.

In one embodiment, the treatment methods of the present invention comprise administering to a patient in need thereof a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention. Various embodiments of the present invention encompass the treatment of the diseases mentioned herein by administering to a patient in need thereof a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention.

In one embodiment, a compound of the invention or a pharmaceutical composition comprising a compound of the invention may be administered by any suitable route of administration, including systemic and topical administration. Systemic administration includes oral, parenteral, transdermal and rectal administration. Typical parenteral administration refers to administration by injection or infusion, including intravenous, intramuscular, and subcutaneous injection or infusion. Topical administration includes application to the skin and intraocular, otic, intravaginal, inhalation, and intranasal administration. In one embodiment, a compound of the invention or a pharmaceutical composition comprising a compound of the invention may be administered orally. In another embodiment, a compound of the invention or a pharmaceutical composition comprising a compound of the invention may be administered by inhalation. In yet another embodiment, a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention may be administered intranasally.

In one embodiment, a compound of the invention or a pharmaceutical composition comprising a compound of the invention may be administered once or several times at different time intervals over a specified period of time according to a dosing regimen. For example, once, twice, three times or four times daily. In one embodiment, the administration is once daily. In yet another embodiment, the administration is twice daily. The administration may be carried out until the desired therapeutic effect is achieved or the desired therapeutic effect is maintained indefinitely. Suitable dosing regimens for the compounds of the invention or pharmaceutical compositions comprising the compounds of the invention depend on the pharmacokinetic properties of the compound, such as absorption, distribution and half-life, which can be determined by the skilled person. In addition, the appropriate dosage regimen, including the duration of the regimen, of the compound of the invention or of the pharmaceutical composition containing the compound of the invention depends on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient being treated, the nature of concurrent therapy, the desired therapeutic effect, and other factors within the knowledge and experience of the skilled artisan. Such a skilled artisan will also appreciate that appropriate dosage regimens may be required to be adjusted for the individual patient's response to the dosage regimen, or as the individual patient needs to change over time.

The compounds of the present invention may be administered simultaneously, or before or after, one or more other therapeutic agents. The compounds of the invention may be administered separately from the other therapeutic agents, by the same or different routes of administration, or in the same pharmaceutical composition. This is selected by the person skilled in the art according to the physical circumstances of the patient, such as health, age, weight, etc. If formulated as a fixed dose, such combination products employ the compounds of the present invention (within the dosage ranges described herein) and the other pharmaceutically active agents (within their dosage ranges).

Accordingly, in one aspect, the present invention includes a combination comprising an amount of at least one compound of the present invention, or a pharmaceutically acceptable salt, solvate, ester or prodrug thereof, and an effective amount of one or more of the additional therapeutic agents described above.

In addition, the compounds of the present invention may be administered in the form of a prodrug. In the present invention, a "prodrug" of a compound of the present invention is a functional derivative that, when administered to a patient, is ultimately released in vivo from the compound of the present invention. When administering the compounds of the present invention in prodrug form, one skilled in the art can practice one or more of the following: (a) altering the in vivo onset time of the compound; (b) altering the duration of action of the compound in vivo; (c) altering the in vivo delivery or distribution of the compound; (d) altering the in vivo solubility of the compound; and (e) overcoming side effects or other difficulties faced by the compounds. Typical functional derivatives useful for preparing prodrugs comprise variants of the compounds which are cleaved in vivo either chemically or enzymatically. These variants, which involve the preparation of phosphates, amides, esters, thioesters, carbonates and carbamates, are well known to those skilled in the art.

Use of the Compounds and pharmaceutical compositions of the invention

The compound and the pharmaceutical composition provided by the invention can be used for preparing medicines for inhibiting chymotrypsin-like enzyme, and can also be used for preparing medicines for treating or preventing heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal failure, nephropathy, fibrosis diseases of internal organs and skin fibrosis diseases.

In the context of the present invention, a disease of the cardiovascular system or a cardiovascular disease is understood to mean, for example, the following diseases: acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina, myocardial ischemia, myocardial infarction, shock, atherosclerosis, cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, preeclampsia, inflammatory cardiovascular diseases, peripheral and cardiovascular diseases, peripheral perfusion disorders, pulmonary hypertension, coronary and peripheral arterial spasm, thrombosis, thromboembolic diseases, edema development (e.g., pulmonary edema, cerebral edema, renal edema, or edema associated with heart failure) and restenosis (e.g., restenosis following thrombolytic therapy, Percutaneous Transluminal Angioplasty (PTA), percutaneous coronary angioplasty (PTCA), cardiac transplantation and bypass surgery), and microvascular and macrovascular injury (vasculitis), reperfusion injury, arterial and venous thrombosis, Microalbuminuria, myocardial insufficiency, endothelial dysfunction, peripheral and cardiovascular disease, peripheral perfusion dysfunction, heart failure-associated edema, elevated levels of fibrinogen and low-density LDL, and elevated concentrations of plasminogen activator/inhibitor 1 (PAI-1).

In the context of the present invention, the term "heart failure" also includes more specific or related types of diseases, such as acute decompensated heart failure, right heart failure, left heart failure, global failure, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, heart valve defects, heart failure associated with heart valve defects, mitral stenosis, mitral insufficiency, aortic stenosis, aortic insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary stenosis, pulmonary insufficiency, comorbid heart valve defects, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, heart storage disorders, and diastolic and systolic heart failure.

The compounds of the present invention may be used in, but are in no way limited to, the prevention, treatment, or alleviation of diseases associated with chymase by administering to a patient an effective amount of a compound or a pharmaceutical composition of the present invention. The diseases related to chymase further include, but are not limited to, heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal failure, renal disease, fibrotic disorders of internal organs, and skin fibrosis.

In addition to being beneficial for human therapy, the compounds and pharmaceutical compositions of the present invention may also find application in veterinary therapy for pets, animals of the introduced species and mammals in farm animals. Examples of other animals include horses, dogs, and cats. Herein, the compound of the present invention includes pharmaceutically acceptable derivatives thereof.

General synthetic procedure

To illustrate the invention, the following examples are set forth. It is to be understood that the invention is not limited to these embodiments, but is provided as a means of practicing the invention.

In general, the compounds of the invention can be prepared by the processes described herein, unless otherwise indicated, wherein the substituents are as defined in formula (I) or formula (IIa) or formula (IIb) or formula (IIc). The following reaction schemes and examples serve to further illustrate the context of the invention.

Those skilled in the art will recognize that: the chemical reactions described herein may be used to suitably prepare a number of other compounds of the invention, and other methods for preparing the compounds of the invention are considered to be within the scope of the invention. For example, the synthesis of those non-exemplified compounds according to the present invention can be successfully accomplished by those skilled in the art by modification, such as appropriate protection of interfering groups, by the use of other known reagents in addition to those described herein, or by some routine modification of reaction conditions. In addition, the reactions disclosed herein or known reaction conditions are also recognized as being applicable to the preparation of other compounds of the present invention.

The examples described below, unless otherwise indicated, all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers and used without further purification unless otherwise indicated.

¹H NMR spectra were recorded using a Bruker 400MHz or 600MHz NMR spectrometer.¹H NMR Spectrum in CDC1₃、DMSO-d₆、CD₃OD or acetone-d₆TMS (0ppm) or chloroform (7.26ppm) was used as a reference standard for the solvent (in ppm). When multiple peaks occur, the following abbreviations will be used: s (singlets, singlet), d (doublets ), t (triplets, triplets), q (quatets, quartets), m (multiplets ), br (broadpededwideams), brs (broadpedsinglets, wideadlets), dd (doublets ), ddd (doublets, doublets), dt (doublets, triplets, doublets), td (triplets of doublets, triplets), tt (triplets of triplets, triplets). Coupling constant J, expressed in Hertz (Hz).

The conditions for determining low resolution Mass Spectrometry (MS) data were: agilent 6120 four-stage rod HPLC-M (column model: Zorbax SB-C18, 2.1X 30mm,3.5 micron, 6min, flow rate 0.6 mL/min. mobile phase 5% -95% (CH with 0.1% formic acid) ₃CN) in (H containing 0.1% formic acid)₂O) by electrospray ionization (ESI) at 210nm/254nm, with UV detection.

The following acronyms are used throughout the invention:

the following synthetic schemes describe the procedures for preparing the compounds disclosed herein, except as otherwise indicated, wherein R¹And R²Having the definitions set out in the present invention.

Synthesis scheme 1

Wherein PMB is p-methoxybenzyl, i.e. PMB is p-methoxybenzyl

Compounds of formula (M11) can be prepared by this synthesis scheme 1, where het is a 5-6 membered heteroaromatic ring: carrying out esterification reaction on the compound shown in the formula (M1) to obtain a compound shown in a formula (M2); reacting the compound shown in the formula (M2) with 4-methoxybenzyl chloride to obtain a compound shown in a formula (M3); hydrogenating and reducing the compound shown as the formula (M3) to obtain a compound shown as a formula (M4); reacting the compound shown as the formula (M4) with phenyl chloroformate to obtain a compound shown as a formula (M5); reacting the compound shown in the formula (M5) with the compound shown in the formula (M6) to obtain a compound shown in the formula (M7); ring closing the compound shown as the formula (M7) to obtain a compound shown as a formula (M8); reacting the compound shown in the formula (M8) with the compound shown in the formula (M9) to obtain a compound shown in the formula (M10); the compound represented by the formula (M10) is deprotected under acidic conditions to give a compound represented by the formula (M11).

Synthesis scheme 2

Compounds of formula (M18) can be prepared by this synthesis scheme 2, wherein, X, Y, W and Z are each independently CH or N: nucleophilic substitution reaction is carried out on the compound shown as the formula (M12) and the compound shown as the formula (M13) to obtain the compound shown as the formula (M14); carrying out condensation reaction on the compound shown in the formula (M14) to obtain a compound shown in a formula (M15); carrying out a ring closure reaction on the compound shown in the formula (M15) and CDI to obtain a compound shown in a formula (M16); the compound shown in the formula (M16) and the compound shown in the formula (M17) are subjected to coupling reaction to obtain the compound shown in the formula (M18).

Synthesis scheme 3

The compound represented by formula (M26) can be prepared by this synthesis scheme 3: nucleophilic substitution reaction is carried out on the compound shown in the formula (M19) and the compound shown in the formula (M20) to obtain the compound shown in the formula (M21); hydrogenating and reducing the compound shown as the formula (M21) to obtain a compound shown as a formula (M22); carrying out a ring closure reaction on the compound shown in the formula (M22) and CDI to obtain a compound shown in a formula (M23); carrying out coupling reaction on the compound shown in the formula (M23) and the compound shown in the formula (M24) to obtain a compound shown in the formula (M25); the compound represented by the formula (M25) undergoes an insertion-carbonyl reaction to give a compound represented by the formula (M26).

The compounds, pharmaceutical compositions and uses thereof provided by the present invention are further illustrated in the following examples.

Examples

Example 2

Synthesis of 4- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -6- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 4-dihydro-5H-pyrazolo [4,3-d ] pyrimidine-5, 7(6H) -dione

The method comprises the following steps: synthesis of 6-nitrobenzo [ d ] oxazole-2 (3H) -one

A mixed solution of 2-amino-5-nitrophenol (50.0g,324mmol) and triethylamine (119mL,856mmol) in methylene chloride (300mL) was slowly added dropwise to a solution of triphosgene (58.9g,198mmol) in methylene chloride (300mL) while cooling on ice, and the reaction was stirred at room temperature for 1 hour. Adding saturated ammonium chloride aqueous solution (300mL) into the reaction mixture for quenching, stirring for 20 minutes, filtering and drying to obtain a small amount of solid product; the filtrates were separated, the aqueous phase was extracted with dichloromethane (400 mL. times.2), and the organic phases were combined and dried over anhydrous sodium sulfate. Filtration and evaporation of the solvent from the filtrate under reduced pressure combined with a small amount of the solid product obtained before to give the title compound as a yellow solid (58.4g, 99.9%).

¹H NMR(400MHz,CDCl₃)δ(ppm)8.25(dd,J＝8.6,2.0Hz,1H),8.12(d,J＝1.9Hz,1H),7.10(d,J＝8.6Hz,1H).

Step two: synthesis of 3-methyl-6-nitrobenzo [ d ] oxazol-2 (3H) -one

To a solution of 6-nitrobenzo [ d ] oxazol-2 (3H) -one (58.4g,324mmol) in N, N-dimethylformamide (300mL) was added potassium carbonate (134g,971.01mmol), and iodomethane (30.3mL,487mmol) was added dropwise under ice-bath, followed by stirring at room temperature for 16 hours. The reaction mixture was quenched with water (1500mL), filtered, and the filter cake dried to give the title compound as a yellow solid (62.9g, 99.9%).

Step three: synthesis of 6-amino-3-methylbenzo [ d ] oxazol-2 (3H) -one

3-methyl-6-nitrobenzo [ d ] oxazol-2 (3H) -one (62.9g,324mmol), tetrahydrofuran (400mL), methanol (400mL) and palladium on carbon (12.6g,3.87mmol) were charged to an autoclave, and the mixture was replaced with hydrogen 3 times, hydrogen was introduced, and the reaction was warmed to 80 ℃ and stirred for 24 hours. The reaction mixture was filtered, the solvent was evaporated from the filtrate under reduced pressure, and the resulting residue was added to petroleum ether/ethyl acetate (500mL/50mL), heated for beating, and filtered with suction to give the title compound as a pale yellow solid (46.0g, 86.5%).

¹H NMR(400MHz,CDCl₃)δ(ppm)6.75(d,J＝8.2Hz,1H),6.63(d,J＝2.0Hz,1H),6.53(dd,J＝8.2,2.1Hz,1H),3.66(s,2H),3.36(s,3H).

Step four: synthesis of 6-bromo-3-methylbenzo [ d ] oxazol-2 (3H) -one

To a solution of cuprous bromide (17.4g,91.4mmol) in acetonitrile (100mL) was slowly added tert-butyl nitrite (13.3mL,110mmol) dropwise at 50 deg.C, stirred for 0.5H, added a solution of 6-amino-3-methylbenzo [ d ] oxazol-2 (3H) -one (10.0g,60.9mmol) in acetonitrile (100mL) dropwise, and heated to 80 deg.C for 6H. The reaction mixture was evaporated under reduced pressure to remove the solvent, and the resulting residue was isolated and purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 20/1-10/1) to give the title compound as a yellow solid (11.81g, 85%).

¹H NMR(400MHz,DMSO-d₆)δ(ppm)7.40–7.34(m,2H),6.86(d,J＝8.2Hz,1H),3.41(s,3H).

Step five: synthesis of 3-methyl-6- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) benzo [ d ] oxazol-2 (3H) -one

To a solution of 6-bromo-3-methylbenzo [ d ] oxazol-2 (3H) -one (5.10g,22.4mmol) in N, N-dimethylformamide (100mL) was added bisphenopinacol borate (6.95g,26.8mmol), potassium acetate (8.78g,89.5mmol), [1, 1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (II) dichloromethane complex (1.82g,2.23mmol), and reacted at 80 ℃ for 3.5H under nitrogen. The reaction mixture was evaporated under reduced pressure to remove a part of the solvent, water (80mL) was added, extraction was performed with ethyl acetate (100 mL. times.2), the organic phase was washed with saturated brine (80 mL. times.2), dried over anhydrous sodium sulfate, and filtered to remove the solvent under reduced pressure to obtain the title compound as a brown solid (6.15g, 100%).

¹H NMR(400MHz,CDCl₃)δ(ppm)7.61(d,J＝7.7Hz,1H),7.55(s,1H),6.93(d,J＝7.7Hz,1H),3.37(s,3H),1.30(s,12H).

Step six: synthesis of (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) boronic acid

To a solution of 3-methyl-6- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) benzo [ d ] oxazol-2 (3H) -one (6.15g,22.4mmol) in acetone (120mL) and water (120mL) were added sodium periodate (28.7g,134mmol) and ammonium acetate (6.89g,89.4mmol), and the mixture was stirred at room temperature for 11 hours. The reaction mixture was evaporated under reduced pressure to remove most of the solvent, water (200mL) was added and stirred overnight, filtered, the filter cake was washed with water (50mL), dried in vacuo, and the crude product was isolated and purified by silica gel column chromatography (dichloromethane/ethyl acetate (v/v) ═ 10/1-4/1) to give the title compound as a brown solid (3.10g, 71.9%).

MS(ESI,pos.ion)m/z:194.1[M+H]⁺.

¹H NMR(400MHz,DMSO-d₆)δ(ppm)8.07(s,2H),7.67(d,J＝7.7Hz,1H),7.63(s,1H),7.21(d,J＝7.7Hz,1H),3.33(s,3H).

Step seven: synthesis of N-benzyl-4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine

To a solution of 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-one (10.0g,50.0mmol) in dichloromethane (200mL) was added benzylamine (6.42g,59.9mmol) and ethyl titanate (20.4mL,74.9mmol) and stirred at room temperature for 1H. Sodium borohydride (3.78g,99.9mmol) was added portionwise at 0 ℃ and stirred at room temperature for 18 h. The reaction mixture was poured into ice water, filtered through celite, and the organic phase was washed with saturated brine (100mL) and dried over anhydrous sodium sulfate. The filtrate was filtered, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 10/1-4/1) to give the title compound as a pale yellow liquid (12.0g, 82.5%).

Step eight: synthesis of 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine

To a solution of N-benzyl-4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine (12.0g,41.2mmol) in tetrahydrofuran (120mL) was added palladium on carbon (1.20g), and the mixture was stirred at room temperature for 24H with hydrogen gas. The reaction mixture was filtered, the solvent was evaporated from the filtrate under reduced pressure, and the resulting residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 20/1-10/1) to give the title compound as a pale yellow liquid (6.17g, 74.4%).

¹H NMR(400MHz,CDCl₃)δ(ppm)7.53(d,J＝7.5Hz,1H),7.49(d,J＝7.7Hz,1H),7.34(t,J＝7.6Hz,1H),4.39(t,J＝7.5Hz,1H),3.19(dd,J＝16.1,8.2Hz,1H),2.95(dt,J＝16.8,8.4Hz,1H),2.57(dtd,J＝11.1,7.8,3.3Hz,1H),1.79(d,J＝8.6Hz,1H).

Step nine: synthesis of 4-nitro-1H-pyrazole-3-carboxylic acid ethyl ester

Thionyl chloride (5.08mL,70.0mmol) was added dropwise to a solution of 4-nitro-1H-pyrazole-3-carboxylic acid (10.0g,63.7mmol) in ethanol (200mL), and the mixture was stirred at room temperature for 21 hours. The reaction mixture was evaporated under reduced pressure to remove the solvent, water (200mL) was added, extraction was performed with ethyl acetate (200 mL. times.2), the organic phase was washed with saturated brine (200mL), dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to give the title compound as a white solid (11.5g, 97.6%).

Step ten: synthesis of 1- (4-methoxybenzyl) -4-nitro-1H-pyrazole-3-carboxylic acid ethyl ester

To a solution of ethyl 4-nitro-1H-pyrazole-3-carboxylate (11.5g,62.1mmol) in N, N-dimethylformamide (200mL) at 0 ℃ was added NaH (2.48g,62.0mmol), and after stirring for 0.5H, 4-methoxybenzyl chloride (10.1mL,74.5mmol) was added dropwise and the mixture was stirred at room temperature for 18.5H. The reaction mixture was quenched by slow addition of water (100mL), extracted with ethyl acetate (200mL × 2), the organic phase was washed with saturated brine (200mL), dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 10/1-4/1) to give the title compound as a colorless liquid (14.0g, 73.8%).

¹H NMR(400MHz,CDCl₃)δ(ppm)8.01(s,1H),7.27(d,J＝8.4Hz,2H),6.94(d,J＝8.6Hz,2H),5.27(s,2H),4.46(q,J＝7.1Hz,2H),3.83(s,3H),1.41(t,J＝7.1Hz,3H).

Step eleven: synthesis of 4-amino-1- (4-methoxybenzyl) -1H-pyrazole-3-carboxylic acid ethyl ester

To a solution of ethyl 1- (4-methoxybenzyl) -4-nitro-1H-pyrazole-3-carboxylate (14.0g,45.9mmol) in methanol (200mL) was added palladium on carbon (1.40g,21.4mmol), and the mixture was stirred at room temperature for 20 hours under hydrogen gas. The reaction mixture was filtered, the solvent was evaporated from the filtrate under reduced pressure, and the crude product was purified by silica gel column chromatography (dichloromethane/ethyl acetate (v/v) ═ 10/1-4/1) to give the title compound as a pale yellow liquid (11.4g, 90.3%).

MS(ESI,pos.ion)m/z:276.2[M+H]⁺.

¹H NMR(400MHz,CDCl₃)δ(ppm)7.18(d,J＝8.1Hz,2H),6.85(m,3H),5.17(s,2H),4.41(qd,J＝7.1,0.8Hz,2H),3.78(d,J＝0.9Hz,3H),1.41(td,J＝7.1,0.8Hz,3H).

Step twelve: synthesis of ethyl 1- (4-methoxybenzyl) -4- ((phenoxycarbonyl) amino) -1H-pyrazole-3-carboxylate

Pyridine (0.64mL,8.0mmol) was added to a solution of 4-amino-1- (4-methoxybenzyl) -1H-pyrazole-3-carboxylic acid ethyl ester (1.10g,4.00mmol) in dichloromethane (20mL), a solution of phenyl chloroformate (0.75mL,6.0mmol) in dichloromethane (20mL) was added dropwise at 0 ℃ under nitrogen, and the mixture was warmed to room temperature and stirred for 6 hours. The reaction mixture was adjusted to pH 6 with diluted hydrochloric acid, extracted with dichloromethane (40 mL. times.2), and the organic phase was dried over anhydrous sodium sulfate. Filtration and evaporation of the solvent under reduced pressure gave a residue which was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 10/1-2/1) to give the title compound as a white solid (1.44g, 91.1%).

¹H NMR(400MHz,CDCl₃)δ(ppm)8.68(s,1H),7.85(s,1H),7.39(t,J＝7.9Hz,2H),7.25(t,J＝7.4Hz,3H),7.21–7.14(m,2H),6.88(d,J＝8.6Hz,2H),5.28(s,2H),4.50(q,J＝7.1Hz,2H),3.80(s,3H),1.48(t,J＝7.1Hz,3H).

Step thirteen: synthesis of ethyl 1- (4-methoxybenzyl) -4- (3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) ureido) -1H-pyrazole-3-carboxylate

To a solution of ethyl 1- (4-methoxybenzyl) -4- ((phenoxycarbonyl) amino) -1H-pyrazole-3-carboxylate (1.43g,3.62mmol) in dimethyl sulfoxide (20mL) was added 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine (606mg,3.0121mmol), and the mixture was warmed to 90 ℃ under nitrogen and stirred for 17.5H. The reaction mixture was cooled to room temperature, water (40mL) was added, extraction was performed with ethyl acetate (80 mL. times.2), and the organic phase was dried over anhydrous sodium sulfate. Filtration and evaporation of the solvent under reduced pressure gave a residue which was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 4/1-1/1) to give the title compound as a pale yellow solid (1.45g, 95.8%).

Fourteen steps: synthesis of 2- (4-methoxybenzyl) -6- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 4-dihydro-5H-pyrazolo [4,3-d ] pyrimidine-5, 7(6H) -dione

To a solution of ethyl 1- (4-methoxybenzyl) -4- (3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) ureido) -1H-pyrazole-3-carboxylate (1.66g,3.30mmol) in DMF (40mL) was added sodium hydride (198mg,4.95mmol) and the mixture was stirred at room temperature for 7H. The reaction mixture was evaporated under reduced pressure to remove part of the solvent, water (80mL) was added, the mixture was stirred overnight, filtered, the filter cake was washed with water (40mL), and the filter cake was dried under reduced pressure to give a pale yellow solid (1.33g, 88.2%).

MS(ESI,neg.ion)m/z:455.1[M-H]⁺.

¹H NMR(600MHz,CDCl₃)δ(ppm)9.97(s,1H),7.41(d,J＝7.5Hz,1H),7.28(t,J＝4.1Hz,2H),7.23(d,J＝7.5Hz,1H),7.17(t,J＝7.6Hz,1H),6.99(s,1H),6.92(d,J＝8.6Hz,2H),6.71(s,1H),5.33(s,2H),3.83(s,3H),3.50(s,1H),3.20–3.11(m,1H),2.64–2.56(m,1H),2.40(s,1H).

Fifteen step Synthesis of 2- (4-methoxybenzyl) -4- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -6- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 4-dihydro-5H-pyrazolo [4,3-d ] pyrimidine-5, 7(6H) -dione

To a solution of 2- (4-methoxybenzyl) -6- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 4-dihydro-5H-pyrazolo [4,3-d ] pyrimidine-5, 7(6H) -dione (1.33g,2.91mmol) in acetonitrile (10mL) was added (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) boronic acid (843mg,4.3688mmol), copper acetate (794mg,4.3715mmol), triethylamine (0.88mL,6.3mmol), dimethyl sulfoxide (0.40mL,8.8mmol), and molecular sieve (1.0g), and the mixture was stirred at room temperature for 20H under nitrogen. The reaction mixture was filtered, the solvent was evaporated under reduced pressure, and the resulting residue was isolated and purified by silica gel column chromatography (dichloromethane/ethyl acetate (v/v) ═ 50/1-20/1) to give the title compound as a yellow solid (1.70g, 96.6%).

MS(ESI,pos.ion)m/z:604.1[M+H]⁺.

¹H NMR(400MHz,CDCl₃)δ(ppm)7.46(d,J＝7.4Hz,1H),7.30(s,1H),7.23(t,J＝6.9Hz,3H),7.22–7.13(m,2H),7.03(d,J＝8.1Hz,1H),6.87(d,J＝8.6Hz,2H),6.81(s,1H),6.77(s,1H),5.30(s,2H),3.80(s,3H),3.53(s,1H),3.43(s,3H),3.22–3.08(m,1H),2.62(dtd,J＝14.2,9.6,4.7Hz,1H),2.51(ddd,J＝19.6,13.0,6.4Hz,1H).

Sixthly, the steps are as follows: synthesis of 4- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -6- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 4-dihydro-5H-pyrazolo [4,3-d ] pyrimidine-5, 7(6H) -dione

To a reaction flask were added 2- (4-methoxybenzyl) -4- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -6- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 4-dihydro-5H-pyrazolo [4,3-d ] pyrimidine-5, 7(6H) -dione (800mg,1.325mmol) and trifluoroacetic acid (20mL), and the reaction was stirred at 80 ℃ for 2.5H. The reaction mixture was evaporated under reduced pressure to remove the solvent, saturated aqueous sodium bicarbonate was added to adjust pH to 8, the mixture was extracted with ethyl acetate (50mL), the organic phase was collected, washed with saturated brine (30mL), dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to remove the solvent, and the resulting residue was purified by silica gel column chromatography (dichloromethane/ethyl acetate (v/v) ═ 10/1-4/1) to give the title compound as a pale yellow solid (0.60g, 93.7%).

MS(ESI,pos.ion)m/z:484.0[M+H]⁺.

¹H NMR(400MHz,DMSO-d₆)δ(ppm)7.44(ddd,J＝25.5,14.0,7.5Hz,7H),6.57(s,1H),3.40(s,3H),3.31(s,1H),3.17–3.04(m,1H),2.61–2.54(m,1H),2.48–2.44(m,1H).

Example 1: synthesis of 3- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -1- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -3, 9-dihydro-1H-purine-2, 6-dione

The title compound was prepared as a brown solid in 5% yield by the method described in reference example 2 using 5-amino-1H-imidazole-4-carboxylic acid as the starting material.

MS(ESI,pos.ion)m/z:484.0[M+H]⁺；

¹H NMR(400MHz,DMSO-d₆)δ(ppm)7.95(s,1H),7.69–7.20(m,5H),6.59(s,1H),5.33(s,1H),3.49(s,3H),3.32(s,1H),3.10(dd,J＝12.7,6.3Hz,1H),2.05–1.94(m,1H),1.37–1.29(m,1H).

Example 9: 1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -2, 4-dioxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -1,2,3, 4-tetrahydropyrido [3,2-d ] pyrimidine-6-carboxylic acid

The method comprises the following steps: synthesis of 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-ol

To a solution of 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-one (1.00g,5.00mmol) in methanol (10mL) at 0 deg.C was added sodium borohydride (236mg,5.988mmol) slowly and the reaction was continued at 0 deg.C. The reaction mixture was removed most of the solvent under reduced pressure, water (50mL) was added, extraction was performed with ethyl acetate (50 mL. times.2), the organic phases were combined, washed with saturated brine (30 mL. times.2), the organic phase was collected, and concentration under reduced pressure gave the title compound as a yellow oil (1.00g, 99.0%).

Step two: synthesis of 6-bromo-3- ((3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) amino) picolinic acid

To a solution of 6-amino-3-methylbenzo [ d ] oxazol-2 (3H) -one (1.492g,9.09mmol) in tetrahydrofuran (20mL) was added dropwise lithium bistrimethylsilyl amide (23mL,23mmol,1mol/L THF), stirred at-78 deg.C for 15min, then added dropwise a solution of 6-bromo-3-fluoropyridine-2-carboxylic acid (2g,9.09mmol) in THF (20mL), stirred at room temperature for 1H, then allowed to warm to room temperature and stirred overnight. The reaction mixture was adjusted to pH 1-2 with 1N HCl solution, extracted with ethyl acetate (50mL × 2), the organic phase was washed with saturated sodium chloride (50mL), then dried over anhydrous sodium sulfate solid, filtered and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) ═ 100/0-85/15) to give the title compound as a tan solid (1.943g, 58.68%).

MS(ES-API,pos.ion)m/z:364.0[M+H]⁺。

Step three: synthesis of 6-bromo-3- ((3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) amino) pyridinecarboxamide

To a solution of 6-bromo-3- ((3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) amino) picolinic acid (1.943g,5.335mmol) in dichloromethane (50mL) was added oxalyl chloride (0.92mL,10mmol) dropwise followed by N, N-dimethylformamide (0.1mL) dropwise and stirred at room temperature for 5 h. The reaction mixture was concentrated under reduced pressure to give a yellow solid, tetrahydrofuran (40mL) was added, and an aqueous solution (40mL) of ammonium hydroxide (28 mass%) was added dropwise to the above tetrahydrofuran solution, followed by stirring at room temperature overnight. The reaction mixture was filtered, water (50mL) was added to the filtrate, extraction was performed with ethyl acetate (50 mL. times.2), the organic phase was collected, washed with saturated sodium chloride solution (50mL), then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the title compound as a yellow solid (1.55g, 80%)

MS(ES-API,pos.ion)m/z:364.9[M+H]⁺。

Step four: synthesis of 6-bromo-1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) pyrido [3,2-d ] pyrimidine-2, 4(1H,3H) -dione

To a solution of 6-bromo-3- ((3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) amino) pyridinecarboxamide (1.55g,4.27mmol) in N, N-dimethylformamide (40mL) was added sodium hydride (0.341g,8.53mmol, 60 mass%), followed by stirring for 5min, addition of CDI (1.384g,8.279mmol), and then stirring at room temperature overnight. The reaction mixture was added with water (50mL), extracted with ethyl acetate (50 mL. times.2), the aqueous phase was adjusted to pH 1-2 and a large amount of precipitate precipitated out, filtered and dried to give the title compound as a yellow solid (0.862g, 51.9%).

¹H NMR(400MHz,DMSO-d₆)δ(ppm)12.04(s,1H),7.73(d,J＝8.8Hz,1H),7.52(d,J＝1.7Hz,1H),7.47(d,J＝8.3Hz,1H),7.33(dd,J＝8.3,1.8Hz,1H),6.90(d,J＝8.8Hz,1H),3.41(s,3H).

Step five: synthesis of 6-bromo-1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) pyrido [3,2-d ] pyrimidine-2, 4(1H,3H) -dione

To a solution of 6-bromo-1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) pyrido [3,2-d ] pyrimidine-2, 4(1H,3H) -dione (0.862g,2.21mmol) in tetrahydrofuran (7mL) and N, N-dimethylformamide (14mL,180mmol) were added 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-ol (0.537g,2.66mmol) and triphenylphosphine (1.162g,4.386mmol), and the temperature was reduced to-15 ℃. Diisopropyl azodicarboxylate (0.87mL,4.3mmol) was then added dropwise, stirred for 1h at room temperature and stirred overnight. The reaction mixture was added with water (50mL), extracted with ethyl acetate (50mL × 2), the organic phase was collected, washed with a saturated sodium chloride solution (50mL), then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 9/1) to 100% ethyl acetate) to give the title compound as a pale yellow solid (0.491g, 38.7%).

MS(ES-API,pos.ion)m/z:572.9[M+H]⁺.

Step six: synthesis of 1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -2, 4-dioxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -1,2,3, 4-tetrahydropyrido [3,2-d ] pyrimidine-6-carboxylic acid

To a solution of 6-bromo-1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) pyrido [3,2-d ] pyrimidine-2, 4(1H,3H) -dione (0.491g,0.856mmol) in N, N-dimethylformamide (8mL,100mmol) were added sodium formate (0.175g,2.55mmol), palladium acetate (0.012g,0.051mmol) and 1,1' -bis (diphenylphosphino) ferrocene (0.028g,0.050mmol), and after 10min of nitrogen gas introduction, N-diisopropylethylamine (0.28mL,1.7mmol) and acetic anhydride (0.16mL,1.7 mmol). The mixture was heated to 100 ℃ under nitrogen protection for reaction overnight. The reaction mixture was added to water (50mL), extracted with ethyl acetate (50mL × 2), the organic phase was collected, washed with saturated sodium chloride solution (50mL), then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the resulting residue was sent to preparative chromatography for purification to give the title compound as a white solid (0.007g, 2%).

MS(ES-API,neg.ion)m/z:536.9[M-H]⁺；

¹H NMR(400MHz,DMSO-d₆)δ(ppm)8.14(d,J＝8.6Hz,1H),7.63–7.35(m,7H),7.10(d,J＝9.2Hz,1H),6.58(s,1H),3.42(s,3H),3.13(m,2H),2.58(m,2H).

The following compounds of the examples were obtained by carrying out a multi-stage reaction of different starting materials, prepared as described in example 9, with the following structures of the products and their characterization data:

Example 10: synthesis of (R) -3- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -2-oxo-1- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazole-5-carboxylic acid

The method comprises the following steps: synthesis of 6- ((5-bromo-2-nitrophenyl) amino) -3-methylbenzo [ d ] oxazol-2 (3H) -one

To a solution of 4-bromo-2-fluoro-1-nitrobenzene (1.00g,4.55mmol) and 6-amino-3-methylbenzo [ d ] oxazol-2 (3H) -one (746.0mg,4.54mmol) in anhydrous N, N-dimethylformamide (20mL) was added potassium carbonate (1.27g,9.10mmol), and the mixture was heated to 90 ℃ for 22H. The reaction mixture was added with water (50mL), extracted with ethyl acetate (50mL × 2), the organic phases were combined, the organic phases were washed with saturated brine (30mL × 2), the organic phases were collected, dried over anhydrous sodium sulfate, suction-filtered under reduced pressure, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 2/1) to give the title compound as an orange-yellow solid (0.87g, 53%).

MS(ES-API,pos.ion)m/z:364.0[M+H]⁺.

Step two: synthesis of 6- ((2-amino-5-bromophenyl) amino) -3-methylbenzo [ d ] oxazol-2 (3H) -one

To 6- ((5-bromo-2-nitrophenyl) amino) -3-methylbenzo [ d ] oxazol-2 (3H) -one (0.87g,2.4mmol) dissolved in methanol (20mL) was added ammonium chloride (1.30g,24.3mmol) and zinc powder (1.60g,24.4mmol) was added slowly in portions and reacted at room temperature for 4H. The reaction mixture was filtered through celite, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1/1) to give the title compound as a brown solid (0.66g, 83%).

Step three: synthesis of 6- (6-bromo-2-oxo-2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) -3-methylbenzo [ d ] oxazol-2 (3H) -one

To a solution of 6- ((2-amino-5-bromophenyl) amino) -3-methylbenzo [ d ] oxazol-2 (3H) -one (0.66g,2.0mmol) in tetrahydrofuran (20mL) was added CDI (0.64g,3.9mmol) and the reaction was carried out at room temperature for 16H. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 1/1) to give the title compound as a pale yellow solid (0.66g, 93%).

Step four: synthesis of (R) -6- (6-bromo-2-oxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) -3-methylbenzo [ d ] oxazol-2 (3H) -one

(S) -4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-ol (230.0mg,1.14mmol), 6- (6-bromo-2-oxo-2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) -3-methylbenzo [ d ] oxazol-2 (3H) -one (340.0mg,0.94mmol) and triphenylphosphine (495.0mg,1.89mmol) were mixed and dissolved in anhydrous tetrahydrofuran (5mL) and N, N-dimethylformamide (10mL) under nitrogen, cooled to 0 deg.C, diisopropyl azodicarboxylate (0.38mL,1.9mmol) was added dropwise and the reaction was incubated at 0 deg.C for 8H. The reaction mixture was warmed to room temperature, water (50mL) was added, extraction was performed with ethyl acetate (50mL × 2), the organic phases were combined, the organic phase was washed with saturated brine (30mL × 2), the organic phase was collected, dried over anhydrous sodium sulfate, suction filtration was performed under reduced pressure, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 2/1) to give the title compound as a red brown solid (418.0mg, 81.36%).

MS(ES-API,pos.ion)m/z:544.0[M+H]⁺.

Step five: synthesis of (R) -3- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -2-oxo-1- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazole-5-carboxylic acid

To a solution of (R) -6- (6-bromo-2-oxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) -3-methylbenzo [ d ] oxazol-2 (3H) -one (418.0mg,0.77mmol) in anhydrous N, N-dimethylformamide (4.6mL) was added sodium formate (157.0mg,2.31mmol), palladium acetate (9.0mg,0.04mmol), 1,1' -bis (diphenylphosphino) ferrocene (24.0mg,0.04mmol), N-diisopropylethylamine (0.28mL,1.5mmol) and acetic anhydride (0.15mL,1.6mmol) were reacted for 21h under nitrogen after three nitrogen replacements. After cooling, water (40mL) was added to the reaction mixture, the pH was adjusted to about 4 with 1N hydrochloric acid, extraction was performed with ethyl acetate (30mL × 2), the organic phases were combined, washed with saturated brine (30mL × 2), the organic phase was collected, dried over anhydrous sodium sulfate, suction-filtered under reduced pressure, the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 3/1-1/9) to give the title compound as a white solid (226.0mg, 57.77%).

MS(ES-API,pos.ion)m/z:510.0[M+H]⁺.

¹H NMR(400MHz,DMSO-d₆)δ(ppm)7.68(d,J＝5.0Hz,2H),7.62(d,J＝8.2Hz,1H),7.51–7.39(m,4H),6.88(s,1H),6.65(s,1H),6.21(t,J＝8.7Hz,1H),3.42(s,4H),3.21(dd,J＝17.2,8.4Hz,2H),2.67(s,1H).

Example 11: synthesis of 1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -2-oxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazole-5-carboxylic acid

The method comprises the following steps: synthesis of N- (5-bromo-2-nitrophenyl) -4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine

4-bromo-2-fluoro-1-nitrobenzene (500.0mg,2.27mmol) and 4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine (457.0mg,2.27mmol) were mixed and dissolved in anhydrous N, N-dimethylformamide (10mL), potassium carbonate (635.0mg,4.55mmol) was added and the temperature was raised to 90 ℃ for reaction for 2H. The reaction mixture was added with water (50mL), extracted with ethyl acetate (50 mL. times.2), the organic phases were combined, washed with saturated brine (30 mL. times.2), the organic phase was collected, dried over anhydrous sodium sulfate, filtered under reduced pressure with suction, and the solvent was evaporated from the filtrate under reduced pressure to give the title compound as a yellow solid (911.0mg, 99.91%).

Step two: 5-bromo-N¹Synthesis of- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) benzene-1, 2-diamine

To a solution of N- (5-bromo-2-nitrophenyl) -4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-amine (911.0mg,2.27mmol) in methanol (15mL) was added ammonium chloride (1.22g,22.8mmol) and zinc powder (1.49g,22.8mmol) was added slowly in portions and reacted at room temperature for 15H. The reaction mixture was filtered through celite to remove insoluble matter, the filtrate was evaporated under reduced pressure to remove the solvent, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 9/1) to give the title compound as a tan solid (590.0mg, 70.00%).

MS(ES-API,pos.ion)m/z:371.1[M+H]⁺.

Step three: synthesis of 6-bromo-1- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -1, 3-dihydro-2H-benzo [ d ] imidazol-2-one

To 5-bromo-N¹To a solution of (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) benzene-1, 2-diamine (590.0mg,1.59mmol) in tetrahydrofuran (20mL) was added CDI (515.0mg,3.18mmol) and the reaction was carried out at room temperature for 22H. The reaction solution was evaporated under reduced pressure to remove the solvent, and the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 2/1) to give the title compound as a pale yellow solid (0.61g, 97%).

MS(ES-API,pos.ion)m/z:397.0[M+H]⁺.

Step four: synthesis of 6- (5-bromo-2-oxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) -3-methylbenzo [ d ] oxazol-2 (3H) -one

To a solution of 6-bromo-1- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -1, 3-dihydro-2H-benzo [ d ] imidazol-2-one (610mg,1.536mmol) and (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) boronic acid (355mg,1.84mmol) in anhydrous dichloromethane (25mL) was added copper acetate (279.0mg,1.54mmol), triethylamine (0.65mL,4.60mmol) and 4A molecular sieves (3.00g), respectively, and the mixture was reacted at room temperature for 4H under nitrogen. The reaction mixture was filtered through celite to remove insoluble matter, the filter cake was washed with dichloromethane, the filtrate was collected, the solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 3/1) to give the title compound as a yellow oil (764.0mg, 91.40%).

MS(ES-API,pos.ion)m/z:544.0[M+H]⁺.

Step five: synthesis of 1- (3-methyl-2-oxo-2, 3-dihydrobenzo [ d ] oxazol-6-yl) -2-oxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazole-5-carboxylic acid

To a solution of 6- (5-bromo-2-oxo-3- (4- (trifluoromethyl) -2, 3-dihydro-1H-inden-1-yl) -2, 3-dihydro-1H-benzo [ d ] imidazol-1-yl) -3-methylbenzo [ d ] oxazol-2 (3H) -one (418.0mg,0.77mmol) in anhydrous N, N-dimethylformamide (4.6mL) was added sodium formate (157.0mg,2.31mmol), palladium acetate (9.0mg,0.04mmol), 1,1' -bis (diphenylphosphino) ferrocene (24.0mg,0.04mmol), N-diisopropylethylamine (0.28mL,1.5mmol) and acetic anhydride (0.15mL,1.6mmol) were reacted for 21h under nitrogen after three nitrogen replacements. After cooling, the reaction mixture was added with water (40mL), pH was adjusted to about 4 with 1N hydrochloric acid, extracted with ethyl acetate (30mL × 2), the organic phases were combined, washed with saturated brine (30mL × 2), the organic phase was collected, dried over anhydrous sodium sulfate, suction filtered under reduced pressure, the filtrate was evaporated under reduced pressure to remove the solvent, and the obtained residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate (v/v) ═ 3/1 to 1/9) to give the title compound as a white solid (226.0mg, 57.77%).

MS(ES-API,pos.ion)m/z:510.1[M+H]⁺.

¹H NMR(400MHz,DMSO-d₆)δ(ppm)12.66(s,1H),7.77–7.58(m,3H),7.56–7.35(m,4H),7.06(t,J＝11.1Hz,2H),6.23(t,J＝8.4Hz,1H),3.42(s,3H),3.27–3.11(m,2H),2.80–2.58(m,1H),2.45(dd,J＝10.8,6.7Hz,1H).

Biological assay

Example A: enzymatic assay for chymotrypsin-like enzymes

The experimental method comprises the following steps:

1. the enzyme source used was recombinant human chymotrypsin (sigma). The chymotrypsin-like substrate used is N-succinyl-Ala-Ala-Pro-Phe-7-amido-4-methylicoumarin.

2. For this assay, the test substance was diluted in DMSO, 20nL of the test substance (1000X) and 10 μ L of the enzyme solution (2X) were mixed in a 384 well plate and incubated at room temperature for 15 minutes, followed by addition of the substrate solution (2X), and the fluorescence signal emitted at 460nm after excitation at 370nm was read dynamically with Synergy 2.

3. One test compound was assayed twice each at 10 different concentrations from 300nM to 0.0152nM on the same microtiter plate. Data were normalized (enzyme reaction without inhibitor 0% inhibition, total assay components without enzyme 100% inhibition) and IC was calculated using GraphPad Prism 5 software₅₀The value is obtained.

The compounds of the invention were tested in this experiment for inhibition of chymase-like activity and the results are shown in table a.

TABLE A test results for the in vitro inhibition of chymase by the compounds of the invention

Example No. 2	IC₅₀(nM)	Example No. 2	IC₅₀(nM)
				1	17.0	2	5.5
3	7.7	4	5.7
				5	9.2	6	5.9
6a	2.1	7	7.8
				8	6.4	9	5.4

The experimental result shows that the compound has good inhibition effect on chymotrypsin-like enzyme.

In the description herein, references to the description of the term "one embodiment," "an embodiment," "some embodiments," "an example," "a specific example" or "some examples" or the like are intended to mean that a particular feature, structure, material, or characteristic described in connection with the embodiment, or example is included in at least one embodiment, or example of the invention. In this specification, a schematic representation of the above terms does not necessarily refer to the same embodiment, implementation, or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments, implementations, or examples. Furthermore, the various examples, embodiments, or examples described in this specification, as well as features of various examples, embodiments, or examples, may be combined and combined by one skilled in the art without contradiction.

Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.

Claims

1. A compound which is a compound represented by formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof,

wherein: ring A is a 5-6 membered heteroaromatic ring orA benzene ring; e is a bond, -CH₂-or-C (═ O) -;

each R⁰Independently H, D, halogen, C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy, halo C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl, heteroaryl consisting of 5-12 atoms, CN, NO₂、-OR^a、-C(O)R^a1、-C(O)NR^a2R^b、-C(O)OR^a、-NR^a2R^b、-NR^a3C(O)R^a1、-NR^a3C(O)OR^a、-NR^a3C(O)NR^a2R^b、-SO₂R^a1、-SO₂NR^a2R^bor-NR^a3SO₂NR^a2R^bWherein said C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy, halo C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl and heteroaryl of 5 to 12 atoms are independently unsubstituted or substituted by 1, 2, 3, 4 or 5R^mSubstituted;

t is 0, 1, 2, 3 or 4;

R^a、R^a1、R^a2、R^a3And R^bEach independently is H, D, C_1-6Alkyl radical, C_1-6Haloalkyl, C_3-8Cycloalkyl, heterocyclic radical composed of 3-8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms;

each R^mIndependently D, halogen, CN, NO₂、OH、NH₂、C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy or halo C_1-6An alkoxy group;

R¹is composed of

R³is-NRⁿ-, -O-, -S-or-CR^cR^d-；

RⁿIs H, D, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Haloalkyl, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms;

R^cand R^dEach independently is H, D, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Haloalkyl, C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms;

R⁴is H, D, C_1-6Alkyl radical, C_2-6Alkenyl radical, C_2-6Alkynyl, C_1-6Haloalkyl, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms;

R²is composed of

Wherein each R⁵Independently H, D, halogen, NO₂、CN、OH、NH₂、C_1-6Alkyl radical, C_1-6Haloalkyl, C_1-6Alkoxy, halo C_1-6Alkoxy radical, C_3-8Cycloalkyl, heterocyclic group consisting of 3 to 8 atoms, C_6-10Aryl or heteroaryl of 5 to 12 atoms;

m is 0, 1, 2, 3 or 4.

2. The compound of claim 1, wherein R ²Is composed of

3. The compound according to claim 1, which is a compound represented by formula (IIb) or formula (IIc), or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof,

4. a compound according to claim 1 or 3, wherein each R is⁰Independently H, D, F, Cl, Br, C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy, halo C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl, heteroaryl consisting of 5-10 atoms, CN, NO₂、-OR^a、-C(O)R^a1、-C(O)NR^a2R^b、-C(O)OR^a、-NR^a2R^b、-NR^a3C(O)R^a1、-NR^a3C(O)OR^a、-NR^a3C(O)NR^a2R^b、-SO₂R^a1、-SO₂NR^a2R^bor-NR^a3SO₂NR^a2R^bWherein said C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy, halo C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl and heteroaryl of 5 to 10 atoms are independently unsubstituted or substituted by 1, 2, 3, 4 or 5R^mSubstituted;

R^a、R^a1、R^a2、R^a3and R^bEach independently is H, D, C_1-4Alkyl radical, C_1-4Haloalkyl, C_3-6Cycloalkyl, a heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms;

each R^mIndependently D, halogen, CN, NO₂、OH、NH₂、C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy or halo C_1-4An alkoxy group;

Rⁿis H, D, C_1-4Alkyl radical, C _2-4Alkenyl radical, C_2-4Alkynyl, C_1-4Haloalkyl, C_3-6Cycloalkyl, a heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms;

R^cand R^dEach independently is H, D, C_1-4Alkyl radical, C_2-4Alkenyl radical, C_2-4Alkynyl, C_1-4Haloalkyl, C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms;

R⁴is H, D, C_1-4Alkyl radical, C_2-4Alkenyl radical, C_2-4Alkynyl, C_1-4Haloalkyl, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms;

each R⁵Independently H, D, halogen, NO₂、CN、OH、NH₂、C_1-4Alkyl radical, C_1-4Haloalkyl, C_1-4Alkoxy, halo C_1-4Alkoxy radical, C_3-6Cycloalkyl, heterocyclic group consisting of 3 to 6 atoms, C_6-10Aryl or heteroaryl of 5 to 10 atoms.

5. A compound according to claim 1 or 3, wherein ring a is pyrrole, pyrazole, imidazole, triazole, tetrazole, furan, thiophene, thiazole, oxazole, pyridine, pyrimidine, pyrazine, pyridazine or benzene;

each R⁰Independently H, D, F, Cl, Br, NO₂、CN、OH、NH₂Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CF₃、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy, trifluoroethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, -OR ^a、-C(O)R^a1、-C(O)NR^a2R^b、-C(O)OR^a、-NR^a2R^b、-NR^a3C(O)R^a1、-NR^a3C(O)OR^a、-NR^a3C(O)NR^a2R^b、-SO₂R^a1、-SO₂NR^a2R^bor-NR^a3SO₂NR^a2R^bWherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, difluoroethoxy, trifluoroethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furalPyranyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl independently being unsubstituted or substituted by 1, 2, 3, 4 or 5R^mAnd (4) substituting.

6. A compound according to claim 1 or 3, wherein R^a、R^a1、R^a2、R^a3And R^bEach independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CHF₂、-CF₃、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl;

Each R^mIndependently D, F, Cl, Br, I, NO₂、CN、OH、NH₂Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CF₃、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy group, ethoxy group, 1-propoxy group, 2-propoxy group, 1-butoxy group, 2-methyl-1-Propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, trifluoromethoxy, difluoroethoxy, or trifluoroethoxy;

Rⁿh, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CHF₂、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Vinyl, propenyl, allyl, ethynyl, propargyl, 1-propynyl, 1-alkynbutyl, 2-alkynylbutyl, 3-alkynylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

R^cand R^dEach independently H, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH ₂F、-CHF₂、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Vinyl, propenyl, allyl, ethynyl, propargyl, 1-propynyl, 1-propargyl, 2-propargyl, 3-propargyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, or a mixture thereof,Benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

R⁴h, D, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CHF₂、-CH₂CH₂F、-CH₂CHF₂、-CHFCH₂F、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Vinyl, propenyl, allyl, ethynyl, propargyl, 1-propynyl, 1-alkynbutyl, 2-alkynylbutyl, 3-alkynylbutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl;

Each R⁵Independently H, D, F, Cl, Br, NO₂、CN、OH、NH₂Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, -CH₂F、-CH₂Cl、-CHF₂、-CHCl₂、-CF₃、-CH₂CH₂F、-CH₂CH₂Cl、-CH₂CHF₂、-CH₂CHCl₂、-CHFCH₂F、-CHClCH₂Cl、-CH₂CF₃、-CH(CF₃)₂、-CF₂CH₂CH₃、-CH₂CH₂CH₂F、-CH₂CH₂CHF₂、-CH₂CH₂CF₃Methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, 2-methyl-2-propoxy, difluoromethoxy, trisFluoromethoxy, difluoroethoxy, trifluoroethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, naphthyl, benzimidazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, thienyl, thiazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl.

7. The compound according to claim 1 or 3, which is a compound having one of the following structures or a stereoisomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof of the compound having one of the following structures:

8. a pharmaceutical composition comprising a compound of any one of claims 1-7, and optionally further comprising a pharmaceutically acceptable excipient, carrier, adjuvant, or any combination thereof.

9. The pharmaceutical composition according to claim 8, further comprising one or more additional active ingredients selected from the group consisting of: calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, kinase inhibitors, matrix metalloproteinase inhibitors, soluble guanylate cyclase stimulators and activators and phosphodiesterase inhibitors.

10. Use of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to any one of claims 8 to 9 for the manufacture of a medicament for the treatment or prophylaxis of heart failure, pulmonary hypertension, chronic obstructive pulmonary disease, asthma, renal failure, renal disease, fibrotic disorders of internal organs or skin fibrosis.